

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
22 May 2003 (22.05.2003)

PCT

(10) International Publication Number
WO 03/042408 A2

(51) International Patent Classification⁷: C12Q 1/68

Wales College of Medicine, Heath Park, Cardiff CF14 4XN (GB).

(21) International Application Number: PCT/GB02/05103

(74) Agents: NEWELL, William, Joseph et al.; Wynnee-Jones, Laine & James, Morgan Arcade Chambers, 33 St Mary Street, Cardiff CF10 1AF (GB).

(22) International Filing Date:
12 November 2002 (12.11.2002)

(25) Filing Language: English

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(26) Publication Language: English

(30) Priority Data:
0127213.7 12 November 2001 (12.11.2001) GB

(71) Applicant (*for all designated States except US*): UNIVERSITY OF WALES COLLEGE OF MEDICINE [GB/GB]; Heath Park, Cardiff CF4 4XN (GB).

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): COOPER, David, Neil [GB/GB]; Department of Medical Genetics, University of Wales College of Medicine, Heath Park, Cardiff CF14 4XN (GB). PROCTER, Anne, Marie [GB/GB]; Department of Medical Genetics, University of Wales College of Medicine, Heath Park, Cardiff CF14 4XN (GB). GREGORY, John [GB/GB]; Department of Medical Genetics, University of Wales College of Medicine, Heath Park, Cardiff CF14 4XN (GB). MILLAR, David, Stuart [GB/GB]; Department of Medical Genetics, University of

Published:

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



WO 03/042408 A2

(54) Title: METHOD FOR DETECTING GROWTH HORMONE VARIATIONS IN HUMANS, THE VARIATIONS AND THEIR USES

(57) Abstract: The present invention relates to naturally-occurring growth hormone mutations; to a method for detecting them and their use in screening patients for growth hormone irregularities or for producing variant proteins suitable for treating such irregularities. In one aspect there is disclosed a detection method for detecting a variation in *GHI* effective to act as an indicator of *GH* dysfunction in an individual, which detection method comprises the steps of: (a) obtaining a test sample comprising a nucleotide sequence of the human *GHI* gene from the individual; and (b) comparing the sequence obtained from the test sample with the standard sequence known to be that of the human *GHI* gene, wherein a difference between the test sample sequence and the standard sequence indicates the presence of a variation (hereinafter "variant of *GHI*") effective to act as an indicator of *GHI* dysfunction characterised in that the test sample is obtained from an individual, either or both: exhibiting intra-uterine growth retardation (IUGR), defined as sufficient foetal height velocity diagnosed by standard methods known in the art; and/or small for gestational age (SGA), defined as insufficient (small) foetal body size (weight and/or length) for gestational age diagnosed by standard methods known in the art.

**Method for Detecting Growth Hormone Variations in Humans, the Variations
and their Uses**

5 The present invention relates to naturally-occurring growth hormone mutations; to a method for detecting them and their use in screening patients for growth hormone irregularities or for producing variant proteins suitable for treating such irregularities.

10 That human stature was influenced by inherited factors was understood more than a century ago. Although familial short stature, with its normally recessive mode of inheritance, was recognised as early as 1912, it was a further quarter century before such families came to be properly documented in the scientific literature. The recognition that recessively inherited short stature was commonly associated with isolated growth hormone (GH) deficiency only came in 1966.

15 Short stature associated with GH deficiency has been estimated to occur with an incidence of between 1/4000 and 1/10000 live births. Most of these cases are both sporadic and idiopathic, but between 5 and 30% have an affected first-degree relative consistent with a genetic aetiology for the condition. Confirmation of the genetic aetiology of GH deficiency came from the molecular genetic analysis of familial short
20 stature and the early demonstration of mutational lesions in the pituitary-expressed growth hormone (*GHI*) genes of affected individuals. Familial short stature may also be caused by mutation in a number of other genes (*eg POU1F1, PROPI* and *GHRHR*) and it is important to distinguish these different forms of the condition.

25 Growth hormone (GH) is a multifunctional hormone that promotes post-natal growth of skeletal and soft tissues through a variety of effects. Controversy remains as to the relative contribution of direct and indirect actions of GH. On one hand, the direct effects of GH have been demonstrated in a variety of tissues and organs, and GH receptors have been documented in a number of cell types. On the other hand,
30 a substantial amount of data indicates that a major portion of the effects of GH are mediated through the actions of GH-dependent insulin-like growth factor I (IGF-I). IGF-1 is produced in many tissues, primarily the liver, and acts through its own receptor to enhance the proliferation and maturation of many tissues, including bone, cartilage, and skeletal muscle. In addition to promoting growth of tissues, GH has also

been shown to exert a variety of other biological effects, including lactogenic, diabetogenic, lipolytic and protein anabolic effects, as well as sodium and water retention.

- 5 Adequate amounts of GH are needed throughout childhood to maintain normal growth. Newborns with GH deficiency are usually of normal length and weight. Some may have a micropenis or fasting hypoglycemia in conjunction with low linear postnatal growth, which becomes progressively retarded with age. In those with isolated growth hormone deficiency (IGHD), skeletal maturation is usually delayed in association with their height retardation. Truncal obesity, facial appearance younger than expected for their chronological age and delayed secondary dentition are often present. Skin changes similar to those seen in premature ageing may be seen in affected adults.
- 10
- 15 Familial IGHD comprises several different disorders with characteristic modes of inheritance. Those forms of IGHD known to be associated with defects at the *GHI* gene locus are shown in Table 1 together with the different types of underlying lesion so far detected.

20 **Table 1: Classification of inherited disorders involving the *GHI* gene**

Disorder	Mode of inheritance	Types of gene lesion responsible	GH protein	Deficiency state
IGHD IA	Autosomal recessive	Gross deletions, micro-deletions, nonsense mutations	Absent	Severe short stature. Anti-GH antibodies often produced upon GH treatment, resulting in poor response thereto.
IGHD IB	Autosomal recessive	Splice site mutations	Deficient	Short stature. Patients usually respond well to exogenous GH.
IGHD II	Autosomal dominant	Splice site and intronic mutations, missense mutations	Deficient	Short stature. Patients usually respond well to exogenous GH.

The characterisation of these lesions has helped to provide explanations for the differences in clinical severity, mode of inheritance and propensity to antibody formation in response to exogenously administered GH, between these forms of IGHD. Most cases are sporadic and are assumed to arise from cerebral insults or defects that include cerebral oedema, chromosomal anomalies, histiocytosis, infections, radiation, septo-optic dysplasia, trauma, or tumours affecting the hypothalamus or pituitary. Magnetic resonance imaging examinations detect hypothalamic or pituitary anomalies in about 12% of patients who have IGHD.

10

Although short stature, delayed 'height velocity' or growth velocity, and delayed skeletal maturation are all seen with GH deficiency, none of these is specific for this disorder; other systemic diseases may result in such symptoms. Throughout this specification, 'height velocity' and growth velocity are both to be construed as meaning the rate of change of the subject's or patient's height, such as is measured in centimetres *per* year.

Stimulation tests to demonstrate GH deficiency use L-Dopa, insulin-induced hypoglycaemia, arginine, insulin-arginine, clonidine, glucagon or propranolol. Inadequate GH peak responses (usually <7-10 ng/mL) differ from test to test. Testing for concomitant deficiencies of LH, FSH, TSH and ACTH should be performed to determine the extent of pituitary dysfunction and to plan optimal treatment.

Recombinant-derived GH is available worldwide and is administered by subcutaneous injection. To obtain an optimal outcome, children with IGHD are usually started on replacement therapy as soon as their diagnosis is established. The initial dosage of recombinant GH is based on body weight or surface area, but the exact amount used and the frequency of administration may vary between different protocols. The dosage increases with increasing body weight to a maximum during puberty. Thereafter, GH treatment should be temporarily discontinued while the individual's GH secretory capacity is re-evaluated. Those with confirmed GH deficiency receive a lower dose of exogenous GH during adult life.

Conditions that are treated with GH include (i) those in which it has proven efficacy and (ii) a variety of others in which its use has been reported but not accepted as standard practice. Disorders in which GH treatment has proven efficacy include GH deficiency, either isolated or in association with combined pituitary hormone deficiency (CPHD) and Turner syndrome. The clinical responses of individuals with the first two disorders to GH replacement therapy varies depending on: (i) the severity of the GH deficiency and its adverse effects on growth, the age at which treatment is begun, weight at birth, current weight and dose of GH; and (ii) recognition and response to treatment of associated deficiencies such as thyroid hormone deficiency; and (iii) whether treatment is complicated by the development of anti-GH antibodies. The outcome of treatment for individuals with Turner syndrome varies with the severity of their short stature, their chromosomal complement, and the age at which treatment was begun.

Additional disorders in which the use of GH has been reported include treatment of certain skeletal dysplasias such as achondroplasia, Prader-Willi syndrome, growth suppression secondary to exogenous steroids or in association with chronic inflammatory diseases such as rheumatoid arthritis, in chronic renal failure, extreme idiopathic short stature, Russell-Silver syndrome, and intrauterine growth retardation.

The characterisation of familial IGHD at the molecular genetic level is important for several reasons. The identity of the locus involved will indicate not only the likely severity of growth retardation but, more importantly, the appropriateness or otherwise of the various therapeutic regimens now available. Further, detection of the underlying gene lesions serves to confirm the genetic aetiology of the condition. It may also have prognostic value in predicting (i) the severity of growth retardation and (ii) the likelihood of anti-GH antibody formation subsequent to GH treatment. In some instances, knowledge of the pathological lesion(s) can also help to explain an unusual mode of inheritance of the disorder and is therefore essential for the counselling of affected families. Finally, the characterisation of the mutational lesions responsible for cases of IGHD manifesting a dysfunctional (as opposed to a non-functional) GH molecule could yield new insights into GH structure and function.

At the cellular level, a single GH molecule binds two GH receptor molecules (GHR) causing them to dimerise. Dimerisation of the two GH-bound GHR molecules is believed to be necessary for signal transduction, which is associated with the tyrosine kinase JAK-2. It has been suggested that the diverse effects of GH may be mediated
5 by a single type of GHR molecule that can possess different cytoplasmic domains or phosphorylation sites in different tissues. When activated by JAK-2, these differing cytoplasmic domains can lead to distinct phosphorylation pathways, one for growth effects and others for various metabolic effects.

10 GH is a 22 kDa protein secreted by the somatotroph cells of the anterior pituitary. X-ray crystallographic studies have shown GH to comprise a core of two pairs of parallel alpha helices arranged in an up-up-down-down fashion. This structure is stabilised by two intra-molecular disulphide linkages (Cys53-Cys165 and Cys182-Cys 189). Two growth hormone receptor (GHR) molecules bind to two structurally distinct sites on
15 the GH molecule, a process which proceeds sequentially by GHR binding first at site 1 and then at site 2. The binding of GHR to GH potentiates dimerisation of the GHR molecules.

Scanning mutagenesis studies of the GH molecule have yielded a picture of the
20 binding interactions between GH and its receptor whilst site-directed mutagenesis has been used to probe the function of specific residues. Thus, substitution of Gly120 (in the third alpha helix of human GH) by Arg results in the loss of GHR binding to site 2 thereby blocking GHR dimerisation. Similarly, residue Phe44 of the human GH protein is important for binding the prolactin receptor. Finally, residues Asp115,
25 Gly119, Ala122 and Leu123 have been shown to be critical for the growth enhancing potential of the murine GH molecule.

Interaction of the dimerised GHR with the intracellular tyrosine protein kinase JAK2 leads to tyrosine phosphorylation of downstream signal transduction molecules,
30 stimulation of mitogen-activated protein (MAP) kinases and induction of signal transducers and activators of transcription (STAT proteins). In this way, GH is able to influence the expression of multiple genes through a number of different signalling pathways.

Several different GH isoforms are generated from expression of the *GHI* gene (*GHI* reference sequence is shown in Figure 5). In 9% of *GHI* transcripts, exon 2 is spliced to an alternative acceptor splice site 45bp into exon 3, thereby deleting amino acid residues 32 to 46 and generating a 20 kDa isoform instead of the normal 22 kDa protein. This 20 kDa isoform appears to be capable of stimulating growth and differentiation. The factors involved in determining alternative acceptor splice site selection are not yet characterised but are clearly of a complex nature. A 17.5 kDa isoform, resulting from the absence of codons 32 to 71 encoded by exon 3, has also been detected in trace amounts in pituitary tumour tissue. Splicing products lacking either exons 3 and 4 or exons 2, 3 and 4 have been reported in pituitary tissue but these appear to encode inactive protein products. A 24 kDa glycosylated variant of GH has also been described. The amino acid sequence of the major 22 kDa isoform is presented in Figure 6, which shows the nucleotide sequence of the *GHI* gene coding region and amino acid sequence of the protein including the 26 amino acid leader peptide. Lateral numbers refer to amino acid residue numbering. Numbers in bold flanking vertical arrows specify the exon boundaries. The termination codon is marked with an asterisk.

The gene encoding pituitary growth hormone (*GHI*) is located on chromosome 17q23 within a cluster of five related genes (Figure 1). This 66.5 kb cluster has now been sequenced in its entirety [Chen *et al.* Genomics 4 479-497 (1989) and see Figure 5]. The other loci present in the growth hormone gene cluster are two chorionic somatomammotropin genes (*CSH1* and *CSH2*), a chorionic somatomammotropin pseudogene (*CSHP1*) and a growth hormone gene (*GH2*). These genes are separated by intergenic regions of 6 to 13 kb in length, lie in the same transcriptional orientation, are placentally expressed and are under the control of a downstream tissue-specific enhancer. The *GH2* locus encodes a protein that differs from the *GHI*-derived growth hormone at 13 amino acid residues. All five genes share a very similar structure with five exons interrupted at identical positions by short introns, 260bp, 209bp, 92bp and 253bp in length in the case of *GHI* (Figure 2).

Exon 1 of the *GHI* gene contains 60bp of 5' untranslated sequence (although an alternative transcriptional initiation site is present at -54), codons -26 to -24 and the first nucleotide of codon -23 corresponding to the start of the 26 amino acid leader

sequence. Exon 2 encodes the rest of the leader peptide and the first 31 amino acids of mature GH. Exons 3-5 encode amino acids 32-71, 72-126 and 127-191, respectively. Exon 5 also encodes 112bp 3' untranslated sequence culminating in the polyadenylation site. An *Alu* repetitive sequence element is present 100bp 3' to the *GHI* polyadenylation site. Although the five related genes are highly homologous throughout their 5' flanking and coding regions, they diverge in their 3' flanking regions.

The *GHI* and *GH2* genes differ with respect to their mRNA splicing patterns. As noted above, in 9% of *GHI* transcripts, exon 2 is spliced to an alternative acceptor splice site 45bp into exon 3 to generate a 20 kDa isoform instead of the normal 22 kDa. The *GH2* gene is not alternatively spliced in this fashion. A third 17.5 kDa variant, which lacks the 40 amino acids encoded by exon 3 of *GHI*, has also been reported.

The *CSH1* and *CSH2* loci encode proteins of identical sequence and are 93% homologous to the *GHI* sequence at the DNA level. By comparison with the *CSH* gene sequences, the *CSHP1* pseudogene contains 25 nucleotide substitutions within its "exons" plus a G→A transition in the obligate +1 position of the donor splice site of intron 2 that partially inactivates its expression.

A number of biallelic restriction fragment length polymorphisms (RFLPs) have been reported within the GH gene region. Five of these (two *Bgl*III, two *Msp*I, one *Hinc*I) occur in Caucasians and Blacks whereas a further *Bam*HI polymorphism occurs predominantly in Blacks. Strong linkage disequilibrium has been observed between these polymorphisms consistent with the relatively recent evolutionary origin of the gene cluster. The *Hinc*II and *Bam*HI polymorphisms occur immediately 5' to the *GHI* gene. An *Rsa*I polymorphism occurs in the *GHI* promoter region resulting from an A/G dimorphism at nucleotide -75 whilst a relatively frequent *Sph*I polymorphism remains to be fully characterised. A highly informative (83% heterozygosity) variable number repeat polymorphism has been located some 19kb 3' to the *GHI* gene; formatted for PCR, the 18 distinct alleles of this polymorphism can be distinguished by fragment size (201 to 253bp).

Finally, the *GHI* gene promoter/5'-untranslated region has been found to exhibit a very high level of sequence polymorphism with 17 variant nucleotides within a 570 bp stretch (Table 2A):

- 5 **Table 2A: Known polymorphisms in the human *GHI* gene promoter/5' untranslated region [after Giordano *et al* Human Genetics 100 249-255 (1997) and Wagner *et al* Eur. J. Endocrinol. 137 474-481]. (Figure 3).**

Nucleotide location	Polymorphism (alternative nucleotides)
-476	G/A
-364	G/T
-339	ΔG
-308	T/G
-301	T/G
-278	T/G
-272 to -276	CCAGA/SMRRR
-168	T/C
-75	A/G
-57	G/T
-31	ΔG
-6	G/A
-1	T/A/C
+3	G/C
+16	A/G
+26	A/C
+59	T/G

- 10 The polymorphisms at positions -1, +3 and +59 are predicted to cause amino acid substitutions in the *GHDTA* protein, putatively encoded by this region of the *GHI* gene promoter (see below). Some of the sequence variants occur in the same positions in which the *GHI* gene differs from the other placentally-expressed genes suggesting that the mechanism might be gene conversion and that the placental genes have served
- 15 as donors of the converted sequences.

In a study of prepubertal short children with GH insufficiency, Hasegawa *et al* [J. Clin. Endocrinol Metab 85 1290-1295 (2000)] reported an association between three polymorphisms in the *GHI* gene [IVS4 C→T 1101 (also reported in Table 7A and 7B
5 hereinbelow), T/G -278 and T/G -57] and both GH secretion and height.

Since the first *GHI* gene deletions were reported, a variety of more subtle lesions have been described. In some cases, these lesions have been associated with unusual types of GH deficiency and are potentially important as a means of obtaining new insights
10 into GH structure and function

The gene encoding growth hormone (*GHI*) was one of the first human genes to be cloned and the first gross gene deletions (6.7kb type) responsible for inherited growth hormone deficiency were soon detected by Southern blotting. All gross deletions
15 involving the *GHI* gene result in severe (type IA) deficiency, characterised by the total absence of GH. About 70% of characterised deletions of the *GHI* gene are 6.7 kb in length, whilst most of the remainder are of 7.6 kb or 7.0 kb (Table 2B - Gross deletions involving the *GHI* gene, or in the vicinity of the *GHI* gene, that cause GH deficiency and short stature).

20

Table 2B: Gross deletions involving or in the vicinity of the *GHI* gene

Deletion size (kb)	Loci involved	Comments	Post-treatment antibodies present?
6.7	<i>GHI</i>	Swiss family	Yes
6.7	<i>GHI</i>	Japanese family	Yes
6.7	<i>GHI</i>	Argentinan family of Spanish ancestry. Homozygous.	Yes
6.7	<i>GHI</i>	Austrian family	Yes
6.7	<i>GHI</i>	Brazilian family	Yes
6.7	<i>GHI</i>	Patient with short stature and cystic fibrosis	Yes

6.7	<i>GH1</i>	Various	No
7.6	<i>GH1</i>	Iraqi, Yemeni and Iranian families	No
7.6	<i>GH1</i>	Italian family. Homozygous. Consanguinous marriage	Yes
7.6	<i>GH1</i>	Italian and Turkish families	Yes
7.6	<i>GH1</i>	Spanish family	No
7.6	<i>GH1</i>	Various	Yes
7.0	<i>GH1</i>	Canadian family	Yes
7.0	<i>GH1</i>	Mexican family	Yes
7.0	<i>GH1</i>	Chinese family. Homozygous	no - No treatment with GH.
45	<i>GH1, CSHP1, CSH1, GH2</i>	Turkish family. Homozygous. Consanguinous marriage	Yes
45	<i>GH1, CSHP1, CSH1, GH2</i>	Italian family. Homozygous	Yes
45	<i>GH1, CSHP1, CSH1, GH2</i>	Italian family. Homozygous. Consanguinous marriage	Yes
45	<i>GH1, CSHP1, CSH1, GH2</i>	"Asian" family	No
?	<i>CSH1, GH2, CSH2</i>	Italian family. Heterozygous	No
?	<i>CSH1, GH2, CSH2</i>	Danish family. Compound heterozygous for non-identical deletions	No
Double	(i) <i>GH1</i> (6.7kb) (ii) <i>CSH1, GH2, CSH2</i> (~32kb)	French origin (Romany). Homozygous. Consanguinous marriage.	Yes

In addition, several examples of much more infrequent deletions have been reported. In recent years, various attempts have been made to move away from Southern blotting toward PCR-based approaches as a mutation screening tool. Homozygous *GHI* gene deletions have been fairly readily detected by PCR amplification of the *GHI* gene and flanking regions followed by restriction enzyme digestion of the resulting PCR products. Although this approach has been used successfully to exclude homozygosity for a *GHI* gene deletion in at-risk pregnancies, it is however unable to distinguish homozygosity for the wild-type gene from heterozygosity for a gene deletion. It would also fail to detect deletions other than the relatively short 6.7, 7.0 and 7.6kb deletions that remove only the *GHI* gene.

PCR primers have been designed which immediately flank the *GHI* gene and which generate a 790bp fragment from control DNA samples. Absence of this fragment was held to be indicative of a *GHI* gene deletion but the use of "non-specific PCR fragments" as internal controls for PCR amplification must make the reliability of this method somewhat suspect.

As well as gross deletions, three micro-deletions of the *GHI* gene have been reported; two of these patients were also heterozygous for the 6.7 kb *GHI* gene deletion (Table 3).

Table 3: Micro-deletions in the *GHI* gene causing GH deficiency and short stature

Deficiency type	Deletion (Lower case letters denote the deleted bases. ^ specifies the location of the numbered codon immediately downstream.)	Codon (Numbering is relative to translational initiation codon ATG at -26.)	Post-treatment antibodies present?
IA	GCCTG [^] CTCTGcCTGCCCTGGC	-11	Yes
II	CCCCAGGCGGggatgggggagacctgtaGTC AGAGCCC	Intron 3 (del+28 to +45)	No
IA	TCTGT [^] TTCTCagAGTCTATTCC	54	No

Only seven different single base-pair substitutions have been reported from within the coding region of the *GHI* gene (Table 4).

5 **Table 4: Single base-pair substitutions in the *GHI* coding region causing GH deficiency and short stature**

Deficiency type	Nucleotide substitution	Amino acid substitution	Codon (numbering relative to translational initiation codon ATG at -26)	Post-treatment antibodies present?
IA	ACA→GCA	Thr→Ala	-24	No
IA	TGG→TAG	Trp→Term	-7	No
IA	GAG→TAG	Glu→Term	-4	Yes
II	CGC→TGC	Arg→Cys	77	No
?	CCC→CTC	Pro→Leu	89	No
?	GAC→GGC	Asp→Gly	112	No
?	CGC→CAC	Arg→His	183	No

Two of these single base-pair substitutions are nonsense mutations converting amino acid residues Trp-7 and Glu-4 in the signal peptide to stop codons. These mutations are the only known *GHI* gene lesions to cause type IA deficiency that are not gene deletions. Since these lesions predict termination of translation within the signal peptide, they would be incompatible with the production of a functional GH molecule. The other five single base-pair substitutions (including R→C at codon 77, disclosed in EPA 790 305 in relation to the treatment of gigantism) are missense mutations that result in the production of dysfunctional growth hormone molecules. Such naturally-occurring mutations are very much more informative than artificially-induced mutations, in that the former can, in principle, be related directly to the clinical phenotype *ie* the height of the patient in question.

Single base-pair substitutions in the promoter region of possible pathological significance were first sought by sequencing the promoter region of the *GHI* gene (between -60 and +70 relative to the transcriptional initiation site) in three Chinese patients with IGHD IA and 2 controls. Several differences were noted but these were probable polymorphisms and were not characterised further. As mentioned above, the promoter region of the *GHI* gene has subsequently been shown to exhibit a very high level of sequence polymorphism with 17 variant nucleotides within a 570 bp stretch (Figure 3). However, these sequence variants were not found to be over-represented in patients as compared to controls.

10

GHI promoter variation has also been separately investigated and a total of 22 variant polymorphic sites were detected, mostly single base-pair substitutions: 17 of these occurred in a 550 bp region 5' to the ATG initiation codon, three occurred around position -1075 5' to ATG, and two occurred within intron 1 (IVS1) at positions 76 and 219 respectively [Wagner *et al*, Eur J Endocrinol 137 474-81 (1997)]. All except four of these variants were also noted in controls but these four variants were not considered to be the cause of the growth hormone deficiency. Only one of the variant sites occurred within a sequence homologous to a transcription factor binding site: the alternative presence of CCAGA and GAGAG sequences at -333 within a potential (but not proven) NF-1 binding site.

20

Therefore, to date, no mutations of pathological significance have been reported in the *GHI* gene promoter.

Single base-pair substitutions affecting mRNA splicing have also been described in the *GHI* gene. Most are associated with a comparatively rare dominant form of GH deficiency (Table 5).

25

Table 5: Single base-pair substitutions affecting mRNA splicing and causing GH deficiency and short stature

30

Deficiency type	Nucleotide substitution/	Splice site	Ethno-geographic origin/zygosity

	position		
II	G→A, +1	IVS3 donor	Sweden, North America, Northern Europe, South Africa, Chile/heterozygous
II	G→C, +1	IVS3 donor	Turkish/ heterozygous
II	T→C, +2	IVS3 donor	Russian/heterozygous
II	G→A, +5	IVS3 donor	Chilean/ heterozygous
II	G→C, +5	IVS3 donor	Japanese/ heterozygous
II	T→C, +6	IVS3 donor	Turkish/ heterozygous Asian/ heterozygous
II	G→A, +28	IVS3 donor	?/heterozygous
IB	G→C, +1	IVS4 donor	Saudi Arabian/ homozygous
IB	G→T, +1	IVS4 donor	Saudi Arabian/ homozygous
IB	G→C, +5	IVS4 donor	Bedouin/ heterozygous

The transversions in the intron 4 donor splice site have been shown by mRNA *in vitro* expression analysis of transfected cells to activate a cryptic splice site within exon 4, 73bp 5' to the exon 4 donor splice site. This would predict the generation of an aberrantly spliced product lacking amino acids 103-126 encoded by exon 4 and, as a consequence of a shift in the reading frame, the incorporation of 94 novel amino acids including 29 resulting from read-through of the normally untranslated 3' non-coding region of the *GHI* gene.

Since the region of the GH protein encoded by exons 4 and 5 is thought to be important for correct targeting of the protein to secretory granules, it has been predicted that this aberrant protein would not be secreted normally. However, no antibodies to exogenous GH have been noted in patients with type IB GH deficiency. The avoidance of immune intolerance may thus indicate that at least some of the aberrant protein product could be secreted and that it could be partially stable in the circulation. The seven known splicing mutations within IVS3 (Table 5) are associated with a type II deficiency state manifesting autosomal dominant inheritance through the affected families.

GH deficiency patients with truncating *GHI* mutations or homozygous gene deletions are at considerable risk of developing anti-GH antibodies upon GH treatment. By contrast, we are not aware of any reports describing allo-antibody formation in
5 patients with either missense mutations or single base-pair substitutions within splice sites.

Until now, no other correlations between mutant genotype and clinical phenotype have been reported. The requisite data in the published literature are sparse and very
10 variable in quality, but we have attempted a crude meta-analysis as a means of gauging whether or not patients with gross gene deletions differ from patients with splice site mutations in terms of their clinical and phenotypic sequelae. The height of the patients with *GHI* deletions was found to be on average 7.3 SD below the age-adjusted mean (n=29), as compared with an average of 5.4 SD below the mean (n=17)
15 for the patients with *GHI* splicing mutations. Although bone age delay was greater and growth velocity lower in the deletion patients, such findings are very difficult to interpret since they may be subject to bias of ascertainment.

Since most cases of familial GH deficiency hitherto described are inherited as an
20 autosomal recessive trait, some examples of the inherited deficiency state are likely to have gone unrecognized owing to small family size. Similarly, cases of GH deficiency resulting from *de novo* mutations of the *GHI* gene could be classified as sporadic, and a genetic explanation for the disorder would neither be entertained nor sought. Finally, depending upon the criteria used for defining the deficiency state, it may be that the
25 full breadth of both the phenotypic and genotypic spectrum of GH deficiency may never have come to clinical attention. For these reasons, current estimates of the prevalence of GH deficiency could be inaccurate and may therefore seriously underestimate the true prevalence in the population.

30 The definition of IGHD favoured by many combines (a) severe growth retardation, often - as mentioned above - defined as <-4.5 SD in height; (b) reduced GH response to stimulation/provocation (*ie* a serum GH level of <4 ng/ml); and (c) no other cause for growth retardation. The strict adherence to formal definitions of what constitutes GH deficiency and the fairly uniform acceptance of these criteria, especially criterion

(b), in selecting patients for study [Shalet SM *et al.* *Endocrine Rev* 19 203-223 (1998)] would have served to ensure that the described *GHI* mutational spectrum was not only far from complete but also unrepresentative of the wider mutational spectrum. Thus, mutations responsible for GH deficiency states in which the SD scores were less severe or the GH levels less reduced (*eg* missense mutations within the coding region of the gene or promoter mutations) would have been much less likely to come to clinical attention. Indeed, this may go some way toward explaining why only five different missense mutations have so far been reported in the *GHI* gene, a finding which is virtually unprecedented for a fairly prevalent disorder that has been studied at the molecular level for nearly 20 years (The Human Gene Mutation Database; Krawczak *et al.*, *Hum Mutation* 15, 45-51 (2000)).

The complete absence of GH produces a readily recognisable and severe clinical phenotype that has been extensively studied. In those reported studies in which the phenotype of the patients is less severe and in which patient selection criteria have actually been identified, patient ascertainment strategies have generally used the deviation of an individual's height from the mean height for their age as a diagnostic indicator of growth failure.

The selection of patients using criteria (a) and (b), as defined above, will serve to define patients with a severe degree of IGHD-related growth failure. We have proposed that moderating the criteria applied in selecting patients for study would be likely to lead to the inclusion of patients whose growth failure is a manifestation of a different portion of the GH deficiency spectrum, and which could therefore yield a novel set of underlying mutational lesions. Some of these novel lesions could give rise to stable, yet dysfunctional, GH molecules that would exhibit normal immunological reactivity but little or no biological activity. On the basis of radio-immunoassay test results, dysfunctional GH molecules would have been erroneously regarded as normal. If such dysfunctional variants were to turn out to be common, then it would follow that GH deficiency is being under-diagnosed as a result of our current dependence on radio-immunoassay-based GH "function tests". Further, it would demonstrate an urgent need for the development of a true functional diagnostic assay.

Albertsson-Wiklund *et al* (Horm Res 49(2) 7-13 (1998)) have undertaken a study to characterise the post-natal growth patten and final height of children born small-for-gestational age (SGA) and to evaluate the hormonal status in another group of pre-pubertal children born SGA. They found that the majority achieved a catch-up
5 growth during the first two years of life and had levels of GH-binding protein within the range previously reported for 'normal' children. However, the levels of IGF-1, IGFBP-3 and leptin were significantly reduced. No attempt was made in this study to link SGA to the identification or existence of dysfunctional GH variants.

10 We believe that existing criteria suffer from the disadvantage in that they require the patient or individual concerned to have reached at least infancy for the relevant measurements to be made. Currently, no criteria exist that are based on measurements possible at or before birth. Furthermore, we believe that height velocity is a more
15 sensitive indicator of growth failure than absolute height measurements. The use of foetal height velocity as measured *in utero*, (optionally in conjunction with height velocity at a later developmental stage, and/or growth failure and/or short stature and/or reduced height velocity and/or bone age delay, with other variables being normal), has allowed us to identify a unified group of patients with phenotypes which are less severe than that of classical IGHD patients having no GH, but who are more
20 likely to have lesions of the *GHI* gene than those selected on the basis of height measurements alone.

Accordingly, the present invention provides a detection method for detecting a variation in *GHI* effective to act as an indicator of GH dysfunction in an individual,
25 which detection method comprises the steps of:

- (a) obtaining a test sample comprising a nucleotide sequence of the human *GHI* gene from the individual; and
- (b) comparing the sequence obtained from the test sample with the standard sequence known to be that of the human *GHI* gene, wherein a difference between the
30 test sample sequence and the standard sequence indicates the presence of a variation (hereinafter "variant of *GHI*") effective to act as an indicator of GH dysfunction
characterised in that the test sample is obtained from an individual, either or both: exhibiting intra-uterine growth retardation (IUGR), defined as insufficient foetal height velocity diagnosed by standard methods known in the art; and/or small for

gestational age (SGA), defined as insufficient (small) foetal body size (weight and/or length) for gestational age diagnosed by standard methods known in the art.

For example, accepted methods for determining IUGR are described by Dunn in *Acta*
5 *Pediatr Scand* 319 [Suppl] 7-16 (1985) and de Zegher *et al* in *J Clin Endocrinol Metab*
82:2021-2026 (1997). IUGR can be defined either as an *in utero* assessment or an “at
the time of birth” assessment. Gestation is relevant at all times, either to assess growth
in utero or at birth, and therefore is vital in the judgement of whether a foetus or baby
is growth retarded for the gestation. An *in utero* assessment may comprise two direct
10 intra-uterine growth assessments by taking two ultra-sound measurements at different
times during the gestation of the baby.

An alternative method for determining IUGR comprises length assessed at birth; this
is also a suitable method for determining SGA (length) and is related to the standard
15 length/height charts at gestation for any child. Accordingly, such a determination can
be made without having to know the heights of the parents, as the measurements are
related to general population data. If the measured length differs from the standard
length by at least two standard deviations, then the individual is considered to have
IUGR or is said to be SGA. For SGA, similar determinations can also be made with
20 respect to birth weight; again, 2 SD or more below a population-specific standard is
considered to qualify an individual as SGA. The SGA methods are also known to
those skilled in the art and are described by Usher *et al* in *J Pediatr* 74 901-910
(1969); Niklasson *et al* in *Acta Paediatr Scand* 80 756-762 (1991); and Ranke *et al* in
Horm Res 48 [Suppl 1] 72-4 (1997).

25 Some experts use the terms IUGR and SGA interchangeably, particularly in terms of
length measurements. One condition may also be used as an indicator of the other
condition. For example, SGA based on weight can be important because being of low
weight for gestation (*ie* SGA) is a pointer to having IUGR. However, the two
30 conditions do not always go together: an individual is SGA if they have IUGR, but an
individual can be SGA without being IUGR if the SGA is assessed by weight (and the
individual found to meet the criterion) and the IUGR is assessed by length (and the
individual found not to meet the criterion).

The present invention further provides a variant of *GHI* detected by or detectable according to the above-described method of this invention.

5 The present invention also provides a transcript of a variant of *GHI*, such as a protein (hereinafter 'GH variant') comprising an amino acid sequence encoded by a variant of *GHI*, wherein the variant of *GHI* is one detected by or detectable according to the above-described method of this invention.

10 (The terms 'patient' and 'individual' are used interchangeably in the context of this invention).

In a preferred detection method of this invention, the test sample is obtained from an individual exhibiting one or more further criteria, in addition to IUGR and/or SGA as described above, namely:

- 15 (i) growth failure, defined as a growth pattern [delineated by a series of height measurements; Brook CDG (Ed) Clinical Paediatric Endocrinology 3rd Ed, Chapter 9, p141 (1995, Blackwell Science)] which, when plotted on a standard height chart [Tanner *et al* Arch Dis Child 45 755-762 (1970)], predicts an adult height for the individual which is outside the individual's estimated target adult height range, the
20 estimate being based upon the heights of the individual's parents; and/or
(ii) height velocity below the 25th centile for age; and/or
(iii) bone age delay according to the Tanner-Whitehouse scale of at least two years, when compared with chronological age *except* in either children of five or fewer years old or those exhibiting clinical evidence of pubertal development; and/or
25 (iv) no other disorder known to cause IUGR or SGA, or inclusion in criteria (i) to (iii) above; and/or
(v) a clinical phenotype that resulted in sufficient clinical concern to have warranted GH secretion testing, *regardless* of the type of test, the test results, or indeed whether the child attended for testing .

30

Criteria (iv) and (v) may be summarised as "no identifiable pathology, other than the possibility of a GH axis defect that could account for the observed growth failure". A key criterion is that the clinician assessing the child should have had sufficient concern with regard to the child's growth pattern to warrant GH secretion testing. The children selected exhibited.

Preferably, the criteria (i) through (v) are applied cumulatively, so that each of (i), (ii), (iii), (iv) and (v) must be satisfied with respect to a particular individual/patient. However, in the case of children of five years or younger and those in pubertal development, the bone age delay criterion requires modification to account for the differences in bone development at such stages. Accordingly, it is more preferred that criteria (i), (ii), (iv) and (v) are satisfied.

With respect to the criteria (i) through (iv), each criterion may be assessed according to known methods and parameters readily available and described in the art, as elaborated further below:

Useful as a reference for criterion (i) is Tanner and Whitehouse Arch Dis Child 51 170-179 (1976)]. A patient's target adult height range is calculated as the mid-parental height (MPH) with the range being the 10th to 90th centile for MPH, which is sex-dependent:

MPH if male = [father's height + (mother's height +13)]/2 + or - in the range of from 6 to 8cm, usually 7.5cm; and
MPH if female = [(father's height - 13) + mother's height]/2 + or - in the range of from 6 to 8 cm, usually 6cm

These are standard tests and measurements used in the field of human growth, and any other acceptable method of calculation, can be used to determine growth failure, although the above-described method based on the description in Brook (*ibid*, 1996) regarding the formula to apply for predicting the limits of the target height range and on the description in Tanner (*ibid*, 1970) regarding the standard height charts are preferred according to this invention.

This is therefore a substantially different criterion from those used hitherto in the identification of GH-dysfunctional patients, and involves prediction of the (future) adult height of a patient based on their parents' achieved height.

(ii) Tanner JM, Whitehouse RH Atlas of Children's Growth (1982, London: Academic Press); and Butler *et al* Ann Hum Biol 17 177-198 (1990) are sources for

statistics enabling a determination of the first criterion, viz that the height velocity of the patient is less than the 25th centile for the patient's age.

(iii) The Tanner-Whitehouse scale for assessing years of bone age delay is described
5 by Tanner JM, Whitehouse RH, Cameron N *et al* in *Assessment of Skeletal Maturity and Prediction of Adult Height* (1983, London: Academic Press). In the method of this invention, the individual preferably exhibits bone age delay of about 3.5 to 4 years (when compared with chronological age). Assessment of bone age delay in an individual is subject to a greater level of variation, when carried out more than once,
10 the younger the individual, so, for example, multiple assessments of a child of age two may result in a bone age delay varying by +/- 6 months, but at age 3 might vary by +/- 4 months, and so on.

(iv) Since short stature may also be secondary to conditions other than GH
15 dysfunction, test samples from patients suffering from such disorders are excluded from the method of the invention. That the patient is suffering from no other disorder that might give rise to similar symptoms to that of GH dysfunction is determined by baseline investigations. "Baseline investigations" therefore include tests to exclude, particularly, hypothyroidism; pseudo-hypoparathyroidism; malabsorption syndromes
20 *eg* coeliac disease; renal and hepatic diseases; haematological disorders, such as anaemia; and a karyotype to check that a chromosome disorder such as Turner syndrome is not the cause of the growth failure. The patient may also have had a thorough clinical examination in order to exclude other causes of growth failure, for example, cardiac disease including congenital heart disease; chronic auto-immune
25 conditions, such as rheumatoid arthritis and inflammatory bowel disease; chronic respiratory conditions, such as severe asthma or cystic fibrosis; and skeletal problems, such as achondroplasia. A full medical history will also have been taken and used to complement the medical examination in order to aid the exclusion not only of the physical disorders identified above but also of psycho-social deprivation, another
30 well-recognised cause of growth failure in childhood.

Optionally, (v), the patient may also have been subjected to one or more growth hormone function tests. The term "growth hormone function tests" refers to tests of

growth hormone secretion, such as those stimulation tests mentioned hereinbefore, particularly the insulin-induced hypoglycaemic test (IST).

5 GH function tests are usually carried out on patients who are short; have been clinically assessed and had their height monitored over more than one visit to an endocrine clinic; have no other detectable cause for their growth failure; and therefore warrant being subjected to an assessment of their ability to produce growth hormone secretion from their pituitary gland following an appropriate stimulus, such as the profound drop in blood glucose that results from the administration of intravenous
10 insulin. Preferably, in the method according to this invention, the results of the individual's growth hormone function tests are normal.

In the detection method according to this invention, therefore, the measurements relied on relate to pre- or at-birth criteria, whereas prior art detection methods have
15 focused on post-natal events relating to growth of the individual after birth and the relationship of the individual's height to that of its parents. It is widely believed that GH plays a role in foetal growth but that it is a minor one (Gluckman *et al* in *J Pediatr* 121 920-3(1992)). In addition, the rapid, but rapidly decelerating, growth of the first two to three years of life (the infancy component of growth) appears to be
20 largely nutritionally determined. It is the next phase of growth, the childhood component, which is largely determined by GH secretion (Clinical Paediatric Endocrinology, Third Edition, Edited by Charles G.D Brook chapter 6, page 85-106). The present invention therefore surprisingly has found that pre- or at-birth criteria, such as IUGR and/or SGA can relate to *GHI* status.

25 Increasing the breadth of the *GHI* mutational spectrum will inevitably lead to a re-definition of inherited GH deficiency in molecular genetic terms. Furthermore, the recognition of novel types of short stature must eventually require the reclassification of GH deficiency as a disease entity. This will obviously have important implications
30 for the screening and identification of individuals with short stature in whom the use of growth hormone treatment might be beneficial.

The test sample obtained from the patient in the detection method of the invention preferably comprises genomic DNA extracted from patient lymphocytes by standard

procedures, such as from buccal smears, blood samples or hair. *GHI* gene analysis is thereafter carried out by any suitable method for gene sequencing or polymorphism detection, including but not limited to gel or capillary electrophoresis mass spectrometry and pyrosequencing. It is preferably carried out according to the following steps:

1(a). Amplification, preferably PCR amplification, of a 3.2 kb fragment containing the *GHI* gene in its entirety (promoter, five exons of the coding region, introns and untranslated regions) followed by the nested PCR of smaller, overlapping constituent fragments using primers designed so as to ensure *GHI* gene specificity. As well as using six known primers, the design of novel *GHI*-specific primers has been found to be essential in order to avoid cross-contamination emanating from inadvertent PCR amplification of the paralogous, closely linked and highly homologous *GH2*, *CSH1* and *CSH2* genes, and the *CSHP1* pseudo-gene. Accordingly, the method of the invention may comprise PCR amplification of the *GHI* gene of the individual, or any individual suspected of having dysfunctional GH, using a *GHI* gene-specific fragment, being a fragment unique to the *GHI* gene whose sequence is not found in the four other paralogous (non-*GHI*) genes in the GH cluster, and one or more *GHI* gene-specific primers which cannot bind to the homologous flanking regions in the four other paralogous (non-*GHI*) genes in the GH cluster. Preferably, the entire *GHI* gene is amplified; and/or

1(b). Amplification, preferably, PCR amplification, of all or a fragment of genomic DNA spanning the Locus Control Region (hypersensitive sites I and II) approximately 15 kb upstream of the *GHI* gene of the patient [Jones *et al* Mol Cell Biol 15 7010-21 (1995)]. The Locus Control Region (LCR) is an enhancer region that affects the level and time of *GHI* transcription. The LCR is located ~14 kb 5' to the *GHI* gene and is responsible for the co-ordinate expression of the genes in the GH gene cluster. PCR amplification was carried out, using novel oligonucleotide primers, on two overlapping fragments (254 bp and 258 bp) in some patients (Example 5); and a 1.9kb LCR fragment was amplified in all patients (Example 5A); and

2. Optionally, but preferably, mutational screening of the entire *GHI* gene or fragments thereof by Denaturing High Performance Liquid Chromatography (DHPLC)

using the Transgenomic WAVE™ System [O'Donovan *et al* Genomics 52 44-49 (1998)]. This screening method was selected for use since it is extremely rapid, cheap, sensitive and reproducible and exhibits, at least in our hands, a detection efficiency >95%. "Bandshifts" detected by DHPLC would represent potential DNA sequence variants; (otherwise, direct DNA sequencing of the 3.2 kb *GHI* gene-containing PCR fragment without the DHPLC step may also be employed); and

3. Characterisation of any such variants by DNA sequencing (either by automated or manual methods); and, optionally, but preferably also

4. Functional characterisation of *GHI* gene lesions using methodology appropriate to the location of the lesion and the inferred mechanism of dysfunction.

Therefore, the present invention further provides novel *GHI*-specific primers for use in the analysis of *GHI* as described above and in the examples, which primers include:

primers suitable for use in the DHPLC step (see Example 3, Table 6, for further details):

CTC CGC GTT CAG GTT GGC (GHD1F);
 AGG TGA GCT GTC CAC AGG (GHD1R);
 CTT CCA GGG ACC AGG AGC (GHD2R);
 CAT GTA AGC CAA GTA TTT GGC C (GHD3F);
 GGA GAA GGC ATC CAC TCA CGG (GHD4R);
 TCA GAG TCT ATT CCG ACA CCC (GHD5F);
 CGT AGT TCT TGA GTA GTG CGT CAT CG (GHD6R); and
 TTC AAG CAG ACC TAC AGC AAG TTC G (GHD7F);

and primers suitable for use in the LCR step (all 5'→3'), see also Examples 5 and 5A

GTGCCCAAGCCTTTCCC (LCR15: 1159-1177);
 TGTCAGATGTTTCAGTTCATGG (LCR13: 1391-1412);
 CCTCAAGCTGACCTCAGG (LCR25: 1346-1363); and
 GATCTTGGCCTAGGCCTCG (LCR23: 1584-1602); and also

LCR 5A (5' CCAAGTACCTCAGATGCAAGG 3'); and
LCR 3.0 (5' CCTTAGATCTTGGCCTAGGCC 3'); and also

5 LCR 5.0 (5' CCTGTCACCTGAGGATGGG 3');
LCR 3.1 (5' TGTGTTGCCTGGACCCTG 3');
LCR 3.2 (5' CAGGAGGCCTCACAAGCC 3'); and
LCR 3.3 (5' ATGCATCAGGGCAATCGC 3') are suitable for sequencing the 1.9kb
fragment.

10

Other primers, for use in PCT-amplification of the entire *GH1* gene include:

GH1G5 (5' GGTACCATGGCTACAGGTAAGCGCC 3');
15 GH1G3 (5' CTCGAGCTAGAAGCCACAGCTGCCC 3');
BGH3 (5' TAGAAGGCACAGTCGAGG 3');

GH1R5 (5' ATGGCTACAGGCTCCCGG 3'); and
GH1R3 (5' CTAGAAGCCACAGCTGCCC 3').

20

The detection method of the invention and the variant of *GH1* identifiable or detectable thereby can give rise to the following additional advantages:

1. Expansion of the known spectrum of *GH1* gene mutations by identification and
25 characterisation of new lesions.

2. Evaluation of the role of *GH1* gene mutations in the aetiology of short stature.

3. Identification of the mode of inheritance of novel *GH1* gene lesions.

4. Elucidation of the relationship between mutant genotype and clinical phenotype.

This is deemed essential for the early detection and appropriate clinical management
30 of GH deficiency.

5. Evaluation of the effects of *GH1* mutations on the structure and function of the GH molecule. This is particularly important for the assessment of those children with a clinical phenotype at the milder end of the clinical spectrum of short stature. In this

group of patients, dysfunctional GH may be produced that is immunologically active and therefore falls within the normal range in GH function tests.

6. Development of rapid DNA diagnostic tests for inherited GH deficiency

7. Assessment of our postulate that GH deficiency is currently under-diagnosed and
5 underestimated in the population.

Therefore, the characterisation of further, naturally occurring *GHI* lesions promises to be of considerable importance to studies of GH structure, function and expression. Studies of novel coding sequence variants should increase our understanding not only
10 of GH function, but also of the interactions between GH and its receptor (GHR), and the process of GHR-mediated signal transduction. Insights obtained could be relevant to the rational design of a new generation of therapeutic agents. Similarly, studies of naturally-occurring *GHI* lesions in the promoter region should provide new insights into the control of *GHI* gene expression. Thus it may be seen that a broad spectrum of
15 mutational lesions will necessarily improve our understanding of the relationship between mutant genotype and clinical phenotype in inherited forms of GH deficiency. Clearly, these studies are essential for the early detection and appropriate clinical management of familial GH deficiency.

20 The present invention therefore further provides a variant of *GHI*, which differs from *GHI* and is detectable by the method according to the invention but is not detectable by methods used hitherto. Such *GHI* variants of the invention include those characterised in Example 6 and especially Table 7B hereinafter.

25 As indicated hereinbefore, current tests to assess GH secretion are many and varied and no single currently available investigation is ideal. Since the secretion of human GH is pulsatile, and because the amplitude and frequency of the GH pulses are extremely variable (being influenced by multiple internal and external factors including sleep, exercise, stress and the pubertal stage of the individual concerned),
30 those tests that yield the best information require close supervision of the patient in a dedicated investigation ward. The tests are therefore time-consuming, expensive, and cause considerable stress and distress to the patient and their family. The insulin-induced hypoglycaemic test (IST) is of particular note; it is used by many doctors, as mentioned above, to assess GH secretion but deaths have occurred owing to the

treatment necessary for the hypoglycaemia induced in the patient as a necessary requirement of its successful implementation. It is therefore of paramount importance that the decision to perform an investigation, such as an IST, is most carefully considered before it is given a place in the assessment of a short child. The
5 development of a DNA test for use in screening short patients would therefore have many advantages over the other tests currently available.

Accordingly, the present invention provides a screening method for screening a patient suspected of having dysfunctional GH, which screening method comprises the steps
10 of:

- (a) obtaining a test sample comprising a nucleotide sequence of the human *GHI* gene or a polypeptide encoded thereby from the patient; and
- (b) comparing a region of the sequence obtained from the test sample with the
15 corresponding region of a predetermined sequence
characterised in that the predetermined sequence is selected from a variant of *GHI* or a polypeptide encoded thereby that is detectable according to the above-described method of the present invention.

More specifically, the screening method of the invention is characterised in that the
20 predetermined sequence is an oligonucleotide having a nucleic acid sequence corresponding to a region of a variant *GHI* gene, which region incorporates at least one variation when compared with the corresponding region of the wild type sequence.

25 Especially preferred is when the variation is one detectable by the detection method of the invention, such as any of those identified in Example 6 and Table 7 hereinafter.

Preferably, the test sample comprises genomic DNA, which may be extracted by
conventional methods.

30

Therefore, the present invention further provides a screening method for determining GH dysfunction, comprising:

- (a) obtaining a first test sample from an individual suspected of GH dysfunction; and

- (b) comparing the *GHI* gene or polypeptide encoded thereby, or fragment therefrom (eg cDNA), in the first test sample to the corresponding gene, polypeptide encoded thereby, or fragment thereof of a *GHI* variant obtainable from a second test sample derived from an individual who exhibits one or both of the following features: intra-
- 5 uterine growth retardation (IUGR), defined as insufficient foetal height velocity diagnosed by standard methods known in the art; and/or small for gestational age (SGA), defined as insufficient (small) foetal body size (weight and/or length) for gestational age diagnosed by standard methods known in the art.; and, optionally, one or more of:
- 10 (i) growth failure, defined as a growth pattern [delineated by a series of height measurements; Brook CDG (Ed) Clinical Paediatric Endocrinology 3rd Ed, Chapter 9, p141 (1995, Blackwell Science)] which, when plotted on a standard height chart [Tanner *et al* Arch Dis Child 45 755-762 (1970)], predicts an adult height for the individual which is outside the individual's estimated target adult height range, the
- 15 estimate being based upon the heights of the individual's parents; and/or
- (ii) height velocity below the 25th centile for age; and/or
- (iii) bone age delay according to the Tanner-Whitehouse scale of at least two years, when compared with chronological age *except* in either children of five or fewer years old or those exhibiting clinical evidence of pubertal development; and/or
- 20 (iv) no other disorder known to cause IUGR or SGA, or inclusion in criteria (i) to (iii) above; and/or
- (v) a clinical phenotype that resulted in sufficient clinical concern to have warranted GH secretion testing, *regardless* of the type of test, the test results, or indeed whether the child attended for testing .

25

Conveniently, the present invention provides a screening method for screening an individual suspected of GH dysfunction, which screening method comprises the steps of:

- (a) obtaining a test sample comprising a nucleotide sequence of the human *GHI* gene
- 30 from an individual; and
- (b) comparing a region of the sequence obtained from the test sample with the corresponding region of a predetermined sequence

wherein the predetermined sequence is selected from a *GHI* variant identified or identifiable by a detection method according to this invention.

The predetermined sequence is preferably an oligonucleotide having a nucleic acid
5 sequence corresponding to a region of a variant *GHI* gene, which region incorporates at least one variation when compared with the corresponding region of the wild type sequence.

The first test sample or the test sample in the screening methods of this invention
10 preferably comprises genomic DNA.

In the screening method of the invention, the comparison step may be carried out in conventional manner, for example by sequencing the appropriate region of the *GHI* gene, particularly in the case where relatively few variants are to be
15 detected/compared. Where relatively large numbers of variants are involved, DNA chip technology may be employed, such as wherein the chip is a miniature parallel analytical device that is used to screen simultaneously either for multiple known mutations or for all possible mutations, by hybridisation of labelled sample DNA (cDNA or genomic DNA derived from the patient) to micro-arrays of mutation-
20 specific oligonucleotide probes immobilised on a solid support [Southern, Trends Genet 12 110-115 (1996)].

The advantage of a DNA screening method according to the invention over current tests include:

- 25
1. It involves, for the patient, only a single blood test that can be performed in a clinic. Hospital admission, prolonged medical supervision and repeated blood sampling would not be required as is the case for the majority of currently-available tests. There would therefore be a reduction in the expense incurred, the use of specialist time and
30 the distress caused for each patient tested.

2. Earlier diagnosis of functional GH deficiency in patients would become possible. The ease with which the DNA screen can be performed would allow the clinician to consider such an investigation much earlier in the management of a patient than might otherwise be the case. Currently, owing to the problems inherent in tests for GH secretion, doctors will assess children in the out-patient clinic over a long period of time, sometimes several years, before they will subject a child to an IST. The early diagnosis of a genetic aetiology for GH deficiency would enable earlier treatment with GH thereby bringing forward the opportunity to treat patients appropriately by months, or even years in individuals with a less severe phenotype.

10

3. More patients could be tested for GH dysfunction. The ease of the DNA test would allow the doctor to perform it as part of the initial assessment of all short patients at their first visit to the endocrine clinic. This is likely to reveal patients with lesions of the *GHI* gene that cause severe growth problems and also those with milder lesions (e.g. missense mutations in the coding region). These patients may not previously have come to clinical attention because their clinical/phenotypic problems would not have been severe enough to warrant an IST, but they might nevertheless still benefit from treatment with GH.

15

4. Early identification of patients who will require life-long treatment with GH would be possible. These patients could be identified and treated appropriately without recourse to either initial testing or re-testing for GH secretion, or the use of a period without GH to assess their progress (a “trial without treatment”).

20

5. Easy and early identification of family members with GH dysfunction would become available. Once the genetic lesion responsible for growth problems has been identified in an individual, it is relatively easy to assess other family members for the same genetic lesion and to ascertain whether they would also gain benefit from treatment with GH.

25

6. Accuracy of diagnosis should increase. Tests for GH secretion are notorious for their variability in terms of reproducibility of assay results, both within and between laboratories. DNA screening would make this problem a thing of the past. In addition, GH secretion test results can be very difficult to interpret in certain

situations, for example, if the patient is also hypothyroid or has delayed puberty. DNA screening would remove this doubt and prevent delay in the initiation of GH treatment for those patients in whom its use would be beneficial.

5 Accordingly, the present invention further provides a kit suitable for use in carrying out the screening method of the invention, which kit comprises:

- (a) an oligonucleotide having a nucleic acid sequence corresponding to a region of a variant *GHI* gene, which region incorporates at least one variation according to this
10 invention from the corresponding wild-type sequence; and
(b) an oligonucleotide having a nucleic acid sequence corresponding to the wild-type sequence in the region specified in (a); and, optionally,
(c) one or more reagents suitable for carrying out PCR for amplifying desired regions of the patient's DNA.

15

Such reagents may include, for example, PCR primers corresponding to an exon of the *GHI* gene, and/or primers mentioned herein, especially novel primers mentioned hereinabove; and/or other reagents for use in PCR, such as *Taq* DNA polymerase.

20 Preferably, the oligonucleotides in the kit comprise in the range of from 20 to 25 base-pairs, such as 20 base-pairs for the variant sequences and either 20 for the wild-type in the case where the variant is a single base-pair substitution or 25 base-pairs where the variant is a 5 base-pair deletion. In any case, the oligonucleotides must be selected so as to be unique for the region selected and not repeated elsewhere in the genome.

25

Obviously, in the situation where it is desired to screen for multiple variations, such as in the range of from 15 to 20 or more, this would necessitate a kit comprising up to 40 oligonucleotides or more. In the alternative screening method, therefore, using DNA
30 chip technology, the present invention provides a plurality of oligonucleotides as defined in kit component (a) above immobilised on a solid support.

Other nucleotide detection methods could be used, such as signal amplification methods being pioneered in nanotechnology (such as Q-Dots). Also, single molecule detection methods could be employed (such as STM). In which case, the kit

according to this invention may comprise one or more reagents for use in such alternative methods.

Alternatively, the screening method and corresponding kit according to this invention
5 may be based on one or more so-called 'surrogate markers' that are indicative of or correlated to the presence of a variant of *GHI* or a GH variant, such as proteins/amino acid sequences *eg* antibodies specific for a GH variant or a variant of *GHI*. Such a "surrogate marker" may comprise:

(a) any biomolecule (including, but not limited to, nucleotides, proteins, sugars, and
10 lipids);

(b) a chemical compound (including, but not limited to, drugs, metabolites thereof, and other chemical compounds); and/or

(c) a physical characteristic,

whose absence, presence, or quantity in an individual is measurable and indicative of
15 or correlated with the presence of a GH variant or a variant of *GHI*.

Further, suitable, alternative screening methods according to this invention may further comprise obtaining a test sample comprising a GH variant (*ie* a protein/peptide sequence comprising a variation of hGH, such as one encoded by a variant of *GHI*
20 detected by the method of this invention) that is identifiable by conventional protein sequence methods (including mass spectroscopy, micro-array analysis, pyrosequencing, *etc*), and/or antibody-based methods of detection (*eg* ELISA), and carrying out one or more such protein sequencing method(s).

25 In which alternative cases, the kit according to this invention may comprise one or more reagents for use in such alternative methods.

GHI variants detectable by the detection method of this invention may have additional uses than as standards in a screening test for GH dysfunction. For example, variants
30 other than those where the variation is in the promoter region of the *GHI* gene may be used to treat a patient wherein GH production is over-stimulated, such as in cases of pituitary gigantism or acromegaly.

The present invention further provides:

- (a) for the use of one or more of the GH variants or a variant of *GHI* which comprises two terminating mutations for the identification of individuals who do not produce any growth hormone at all and who would be classified as classical GHD by conventional diagnostic techniques;
- 5 (b) a GH variant or a variant of *GHI* which leads to modified binding of GH to the growth hormone receptor or its binding protein (*ie* the carrier for GH *in vivo*), insomuch as the transport of the variant GH from the pituitary by binding to its binding protein is impaired or inhibited leading to destruction of the unbound protein
- 10 *en route* to the tissue receptor;
- (c) a GH variant or a variant of *GHI* capable of disrupting the formation of the zinc dimer storage form of the GH protein in the pituitary;
- (d) a GH variant or a protein expressed by a variant of *GHI*, being a protein with antagonist properties to the GH receptor and whose receptor binding constant
- 15 determines the amount of extraneous GH (dose) needed to treat a patient in order to overcome the potency and inhibitory action of the variant protein; *ie* the variant protein competes with the wild type to bind to the receptor;
- (e) use of the GH variant or a variant of *GHI* according to the invention for therapeutic, diagnostic or detection methods;
- 20 (f) use of the GH variant or a variant of *GHI* according to the invention for the determination of susceptibility to a disease in an individual;
- (g) use of the GH variant or a variant of *GHI* according to the invention for the determination of susceptibility to diabetes, obesity, infection, cancer or cardiac disease;
- 25 (h) use of the GH variant or a variant of *GHI* according to the invention for determining binding defects and/or pituitary storage defects;
- (i) use of the GH variant or a variant of *GHI* according to the invention for the determination of the diagnostic dose of antagonist treatment in acromegaly;
- (j) use of the GH variant or a variant of *GHI* according to the invention for use in
- 30 medical treatment;
- (k) use of the variant of *GHI* according to the invention for use in gene therapy;
- (l) use of the GH variant or a variant of *GHI* according to the invention for determining one or more polymorphism(s) associated with a disease state;

- (m) use of the GH variant or a variant of *GHI* according to the invention for the preparation of a therapeutic composition, diagnostics composition or kit, or detection kit;
- (n) an oligonucleotide of about 20 nucleotides in length having a nucleic acid sequence corresponding to a region of a variant *GHI* gene, which region incorporates at least one variation from the corresponding wild type sequence, said variation comprising one or more of those according to this invention;
- (o) an oligonucleotide comprising the complement of the oligonucleotide of (n);
- (p) an oligonucleotide of (n), wherein the nucleotide corresponding to the variation is located at the 3' end of the molecule;
- (q) a single-stranded DNA probe that hybridizes to a variant *GHI* gene and not to a wild type *GHI* gene, wherein the variant *GHI* gene is selected from those according to this invention;
- (r) an array of nucleic acid molecules attached to a solid support, the array comprising a single stranded DNA probe according to (q);
- (s) a screening method for screening an individual suspected of GH dysfunction, which screening method comprises the steps of:
- (i) obtaining a test sample comprising a nucleotide sequence of the human *GHI* gene from the individual; and
- (ii) comparing the sequence of a region of the human *GHI* gene from the individual corresponding to a region of a variant *GHI* gene according to (n);
- (t) a method according to (s), wherein the comparing step involves hybridization with the predetermined sequence.;
- (u) a method according to (s), wherein the comparing step comprises amplifying at least a portion of a nucleic acid encoding human GH1;
- (v) a method according to (s), wherein the comparing step comprises amplifying at least a portion of a nucleic acid encoding human GH1 with one or more oligonucleotide(s) selected from those described herein;
- (w) an amplification oligonucleotide selected from those described herein;
- (x) a diagnostic kit comprising the required components for the determination of the identity of one or more variations (including substitutions, insertions or deletions with respect to the wild type) of an individual's *GHI* gene, as described herein, in particular a variation according to one or more of (n) to (q), above, and especially a diagnostic

kit comprising an oligonucleotide for use in amplifying a segment of such a gene comprising a polymorphic site;

- (y) an antibody selected from antibodies to one or more epitopes comprising amino acid positions exhibiting a variation as described herein from the reference hGH sequence and which antibody is capable of distinguishing between the variant and wild type amino acids at that amino acid position; and
- 5 (z) a diagnostic kit comprising an antibody according to (y).

Accordingly, the present invention further provides a composition comprising a GH variant, especially a variant detectable by the detection method of this invention and identified herein, in association with a pharmaceutically acceptable carrier therefor.

10

The present invention will now be illustrated with reference to the following Examples.

15

Example 1 – Patient Selection

Sources of Patients

Children with short stature have been identified through referral to the Regional
5 Paediatric Growth, Endocrine and Diabetes Service at the University of Wales College
of Medicine in Cardiff and by collaboration with other similar UK centres (*viz*
Newport, Birmingham, Bristol, Wrexham, Liverpool, Stoke-on-Trent, Portsmouth and
Southampton). A full clinical history has been taken including family history,
pedigree, documentation of growth parameters and previously-performed endocrine
10 investigations. Accurate auxology was recorded wherever possible for the index case,
parents and siblings. Blood samples for molecular genetic analysis were taken from
the index case and appropriate close relatives. Further families were referred by
Professor John A. Phillips III (Nashville, TN, USA), Dr Mohamad Maghnie (Pavia,
Italy) and Dr Tamas Niederland (Gyor, Hungary). To date, samples from 69 GH-
15 deficient families have been collected.

Criteria used

Criteria used for all patients in Table 5B was SGA, defined as having birth weight
and/or birth length below $-2SD$ for gestation at birth. Those patients having 'Y' in the
20 column headed 'IUGR' also exhibit intra-uterine growth retardation, as defined
hereinabove.

Patients having 'Y' in column headed 'CF' additionally exhibit the following criteria:

- (i) Growth below lower limit of % target height range, determined as defined
25 above per criterion (i) according to the invention;
- (ii) Height velocity $<25^{\text{th}}$ centile;
- (iii) Bone age delay of at least 2, for example in the case of patient 18, 3.5-4 years
when compared with chronological age *except* in either children of five or fewer years
old or those exhibiting clinical evidence of pubertal development;
- 30 (iv) All other investigations normal ie no other disorder known to cause IUGR or
SGA, or inclusion in criteria (i) to (iii) above; and
- (v) Growth hormone secretion tests normal; and

(vi) a clinical phenotype that resulted in sufficient clinical concern to have warranted GH secretion testing, *regardless* of the type of test, the test results, or indeed whether the child attended for testing .

5 In Table 5B: *GH FT: peak: Signifies units (IU/L) of activity in one or more standard Growth Hormone Function Tests. 'Random' denotes GH measurement taken randomly. ND denotes 'test not done'. The height centile is included to demonstrate, with the data provided in Table 7B hereinbelow, that it is not an essential selection
 10 variations in GH/GHI that occur even in patients not having a substantially reduced height.

Table 5B: Patients studied and results of criteria used

Patient No.	IUGR	CF	Height Centile	Growth Velocity Centile (ii)	Bone Age Delay (years) (iii)	GH FT: peak (v)
7		Y	< & parallel to 3rd	25	3	111.3 at 90
10		Y	3rd centile	<25	2	38.7
12		Y	0.4	<25	0.5	not done
18		Y	<3	25	4	18
34		Y	<0.4	<25	0.33 at 1.33	10 random
35		Y		<25		
53		Y	<0.4	<25	2	27.2
57		Y	0.4	<25	1.21 at 2.7	27.3 at 2.5
62		Y	<0.4	<25		27 at 1.33
71		Y	0.4	<25		1.3
72a		Y				
78	Y		<0.4	<25		
79	Y	Y	<0.4	<25		
80			<0.4	<25		
82		Y	<0.4	<25		
83	Y	Y	<0.4	<25		Random normal

Example 2 - Polymerase chain reaction (PCR) amplification of a *GHI*-specific fragment

5 PCR amplification of a 3.2 kb *GHI*-specific fragment has been performed on 83 unrelated patients. Genomic DNA was extracted from patient lymphocytes by standard procedures.

Oligonucleotide primers GH1F (5' GGGAGCCCCAGCAATGC 3'; -615 to -599) and
10 GH1R (5' TGTAGGAAGTCTGGGGTGC 3'; +2598 to +2616) were designed to correspond to *GHI*-specific sequences in order to PCR amplify a 3.2kb single genomic DNA fragment containing the human *GHI* gene using the Expand™ high fidelity system (Roche).

15 Two separate thin-walled 0.65ml PCR tubes were used for each reaction. The first tube contained 500 nanograms (ng) each primer (GH1F and GH1R), 200μM dATP, dTTP, dCTP and dGTP and 200ng of patient genomic DNA made up to a final volume of 25μl with sterile water. The second tube contained 5μl 10x reaction buffer made up to a final volume of 24.25μl with sterile water. Both tubes were placed on ice for 5
20 minutes. After this time, 0.75μl of Expand™ polymerase mix was added to the second tube, the contents mixed and transferred to the first tube. The tube was centrifuged for 30 seconds and the reaction mixture overlaid with 30μl light mineral oil (Sigma). The reaction mixture was then placed in a 480 or 9700 PCR programmable thermal cycler (Perkin Elmer) set at 95°C.

25

The reaction mix was then amplified under the following conditions: 95°C for 2 minutes followed by 30 cycles of 95°C for 30 seconds, 58°C for 30 seconds and 68°C for 2 minutes. For the last 20 cycles, the elongation step at 68°C was increased by 5 seconds per cycle. This was followed by a further incubation at 68°C for 7 minutes
30 and the reaction was then cooled to 4°C prior to further analysis. For each set of reactions, a blank (negative control) was also set up. The blank reaction contained all reagents apart from genomic DNA and was used to ensure that none of the reagents were contaminated.

A one-tenth volume (5 μ l) was analysed on a 1.5% agarose gel to assess whether PCR amplification had been successful before nested PCR was performed. Those samples that had PCR-amplified successfully were then diluted 1 in 100 prior to use for nested PCR.

5

Example 3 - Nested-PCR

Nested PCR was performed on the fragments produced in Example 2 to generate, in each case, seven overlapping sub-fragments that together span the entire *GHI* gene. In addition, the Locus Control Region has been PCR-amplified (see Example 5) in all but three patients.

The seven overlapping sub-fragments of the initial 3.2 kb PCR product were PCR-amplified using *Taq* Gold DNA polymerase (Perkin-Elmer). Oligonucleotides used for these reactions are listed in Table 6 together with their sequence locations as determined from the *GHI* gene reference sequence.

A 1 μ l aliquot of the diluted long (3.2 kb) PCR product was put into a thin-walled 0.2ml PCR tube or into one well of a 96-well microtitre plate. To this was added 5 μ l 10x reaction buffer, 500ng appropriate primer pair (e.g. GH1DF and GH1DR), dATP, dTTP, dCTP and dGTP to a final concentration of 200 μ M, sterile water to a volume of 49.8 μ l, followed by 0.2 μ l *Taq* Gold polymerase.

The tube or microtitre plate was then placed in a Primus 96 thermal cycler (MWG Biotech) and cycled as follows: 12 min 95°C followed by 32 cycles of 95°C for 30 seconds, 58°C for 30 seconds and 72°C for 2 minutes. This was followed by further incubation at 72°C for 10 minutes and the reaction was then cooled to 4°C prior to further analysis.

30

A one-tenth volume (5 μ l) of the reaction mix was analysed on a 0.8% agarose gel to determine that the reaction had worked before denaturing high-pressure liquid chromatography (DHPLC) was performed on a WAVE™ DNA fragment analysis system (Transgenomic Inc. Crewe, Cheshire, UK). To enhance heteroduplex

formation, the PCR product was denatured at 95°C for 5 minutes, followed by gradual re-annealing to 50°C over 45 minutes. Products were loaded on a DNasep column (Transgenomic Inc.) and eluted with a linear acetonitrile (BDH Merck) gradient of 2%/min in a 0.1M triethylamine acetate buffer (TEAA pH 7.0), at a constant flow rate of 0.9ml/minute. The start and end points of the gradient were adjusted according to the size of the PCR product. Analysis took 6.5-8.5 minutes per amplified sample, including the time required for column regeneration and equilibration. Samples were analysed at the Melt temperatures (TM) determined using the DHPLCMelt software (<http://insertion.stanford.edu/melt.html>) and listed in Table 6. Eluted DNA fragments were detected by an UV-C detector (Transgenomic Inc.).

Table 6 Oligonucleotide primers used for DHPLC analysis and DNA sequencing

Fragment	Primer	Sequence (5' to 3')	Position	DHPLC melt temperature
1	GH1DF	CTCCGCGTTCAGGTTGGC	-309 to -292	60°C
	GH1DR	CTTGGGATCCTTGAGCTGG	-8 to +11	
2	GH2DF	GGGCAACAGTGGGAGAGAAG	-59 to -40	63°C
	GH2DR	CCTCCAGGGACCAGGAGC	+222 to +239	
3	GH3DF	CATGTAAGCCCAGTATTTGGCC	+189 to +210	62°C
	GH3DR	CTGAGCTCCTTAGTCTCCTCCTCT	+563 to +586	
4	GH4DF	GACTTTCCTCCGCTGGGAAA	+541 to +560	62°C
	GH4DR	GGAGAAGGCATCCACTCACGG	+821 to +841	
5	GH5DF	TCAGAGTCTATTCCGACACCC	+772 to +792	62°C
	GH5DR	GTGTTTCTCTAACACAGCTCTC	+1127 to +1148	
6	GH6DF	TCCCAATCCTGGAGCCCCACTGA	+1099 to +1122	62°C
	GH6DR	CGTAGTTCCTGAGTAGTGCGTCATCG	+1410 to +1435	
7	GH7DF	TTCAAGCAGACCTACAGCAAGTTCG	+1369 to +1393	57°C and 62°C
	GH7DR	CTTGGTTCCCGAATAGACCCCG	+1731 to +1752	

Example 4 - Cloning and DNA-Sequencing of *GHI*-specific long PCR fragments

Cloning

DHPLC analysis allowed the identification of DNA fragments containing putative DNA sequence changes. To determine which allele possessed the putative sequence change, *GHI*-specific long (3.2 kb) PCR fragments were cloned into the PCR plasmid cloning vector pGEM-T (Promega). Cloning was accomplished by adding 50ng of *GHI*-specific long PCR fragment to 10ng pGEM-T in the presence of 1x reaction buffer and 1 μ l (3 units) T4 DNA ligase in a final volume of 10 μ l. The reactions were incubated for 16 hours at 10°C. The entire reaction mixture was placed in a 1.5ml tube and cooled on ice. 50 μ l DH5 α competent cells (Life Technologies) were added and the tube left on ice for 30 minutes. The mixture was then heat-shocked for 20 seconds at 37°C and returned to ice for 2 minutes. After this time, 0.95ml of YTx2 medium (16g tryptone, 10g yeast extract, 5g NaCl per litre water) was added and the mixture incubated at 37°C for one hour with shaking. The mixture was then plated out onto pre-warmed agar plates containing 50 μ g/ml ampicillin, IPTG and X-gal and incubated at 37°C for 16 hours to allow single colonies to grow.

Eight white colonies from each plate were picked and transferred to a second gridded plate. A small amount of each bacterial colony was PCR-amplified using primers GH1DF and GH1DR (see Example 3, Table 6) and the conditions previously described to determine that the *GHI*-specific long PCR fragment had been successfully cloned.

Clones that contained the *GHI*-specific long PCR fragment were grown in 2ml YTx2 medium; plasmid DNA was extracted from the bacteria using a Qiagen spin miniprep kit according to the manufacturer's instructions. DNA extracted in this way was quantified by measuring its optical density at 260nm and electrophoresed on a 0.8% agarose gel to verify that the size of the clone was correct. Four of these clones were then sequenced.

Automated DNA sequencing

Clones containing the *GHI*-specific long PCR fragment were sequenced with the BigDye sequencing kit (Perkin Elmer) in either 0.2ml tubes or 96-well microtitre plates in a Primus 96 (MWG) or 9700 (Perkin Elmer) PCR thermal cycler.

5 Oligonucleotide primers used for sequencing were:

GH1S1 (5' GTGGTCAGTGTTGGAAGTGC 3': -556 to -537);

GH3DF (5' CATGTAAGCCAAGTATTTGGCC 3': +189 to +210);

GH4DF (5' GACTTTCCCCCGCTGTAAATAAG 3': +541 to +560); and

10 GH6DF (5' TCCCCAATCCTGGAGCCCCACTGA 3': +1099 to +1122).

1µg of cloned DNA was sequenced with 3.2pmol of the appropriate primer and 4µl BigDye sequencing mix in a final volume of 20µl. The tube or microtitre plate was then placed in the thermal cycler and cycled as follows: 2 minutes 96°C followed by
15 30 cycles of 96°C for 30 seconds, 50°C for 15 seconds and 60°C for 4 minutes. The reaction was then cooled to 4°C prior to purification.

Purification was performed by adding 80µl 75% isopropanol to the completed sequencing reaction. This was then mixed and left at room temperature for 30 minutes.
20 The reaction was then centrifuged at 14,000 rpm for 20 minutes at room temperature. The supernatant was then removed and 250µl 75% isopropanol was added to the precipitate. The sample was mixed and centrifuged for 5 minutes at 14,000 rpm at room temperature. The supernatant was removed and the pellet dried at 75°C for 2
25 minutes.

Samples were then analysed on an ABI Prism 377 or 3100 DNA sequencer.

Example 5 - Analysis of the growth hormone locus control region

30 A DNA region approximately 14.5kb upstream of the human *GHI* gene is known to be involved in the tissue-specific and developmental control of *GHI* gene transcription [Jin *et al* Mol Endocrinol 13 1249-1266 (1999)]. This is known as the Locus Control

Region (LCR) and its DNA sequence was obtained from GenBank (Accession Number: AF010280). Nucleotide numbering is based on the GH LCR reference sequence (Figure 4).

The polymorphic site at position 1192 is marked in bold type and underlined. Part of
5 this region was analysed by PCR and DHPLC.

Two overlapping PCR fragments spanning approximately 400bp were generated through the use of novel oligonucleotide primers designed by reference to the available DNA sequence:

10

Fragment 1 primers were LCR15 (5' GTGCCCAAGCCTTTCCC 3': 1159-1177) and

LCR13 (5' TGTCAGATGTTTCAGTTCATGG 3': 1391-1412); and

fragment 2 primers were LCR25 (5' CCTCAAGCTGACCTCAGG 3': 1346-1363)
15 and LCR23 (5' GATCTTGGCCTAGGCCTCG 3': 1584-1602).

PCR was performed using *Taq* Gold polymerase: 1µl patient genomic DNA was placed into a thin walled 0.2ml PCR tube or into one well of a 96-well micotitre plate. To this was added, 5µl 10x reaction buffer, 500ng of the appropriate primer pair (e.g.
20 GH1DF and GH1DR), dATP, dTTP, dCTP and dGTP to a final concentration of 200µM, sterile water to a volume of 49.8µl followed by 0.2µl *Taq* Gold polymerase. The tube or microtitre plate was then placed in a Primus 96 thermal cycler (MWG Biotech) and cycled as follows: 12 minutes 95°C followed by 32 cycles of 95°C for 30 seconds, 58°C for 30 seconds and 72°C for 2 minutes. This was followed by a further
25 incubation at 72°C for 10 minutes and the reaction was then cooled to 4°C prior to further analysis.

A one-tenth volume (5µl) was analysed on a 1.5% agarose gel to determine that the reaction had worked before denaturing high-pressure liquid chromatography (DHPLC)
30 was performed. Analysis by DHPLC was performed as described in Example 3 with a melt temperature of 61°C.

Example 5A – Further Analysis of the growth hormone locus control region

600 ng DNA from 40 control individuals and 40 patients with inherited GH deficiency were used to PCR-amplify a 1.9 kb LCR fragment using the following novel primers:

LCR 5A (5' CCAAGTACCTCAGATGCAAGG 3'); and
LCR 3.0 (5' CCTTAGATCTTGGCCTAGGCC 3'; see Figure 4),

5mM dNTPs and Roche High Fidelity DNA polymerase. Reaction conditions were 98°C x 2 min, 94°C x 15s, 58°C x 30s, 72°C x 1 min x 10 cycles, 58°C x 30s, 72°C x 1min + 5 seconds added on to each successive cycle x 20 cycles. PCR reaction products were separated on a 2% agarose gel and bands corresponding to the LCR fragment excised with a scalpel. Agarose was removed by gel extraction and DNA eluted for sequencing. The 1.9 kb LCR fragment was sequenced on an ABI 3100 automated sequencer using the following novel primers:

LCR 5.0 (5' CCTGTCACCTGAGGATGGG 3');
LCR 3.1 (5' TGTGTTGCCTGGACCCTG 3');
LCR 3.2 (5' CAGGAGGCCTCACAAGCC 3'); and
LCR 3.3 (5' ATGCATCAGGGCAATCGC 3') were used to span the region.

Example 5B – Characterization of *GHI* promoter haplotypes and putative promoter mutations by luciferase reporter gene assay

The QuikChange™ site-directed mutagenesis kit was used to incorporate specific sequence variants into the pGL3-GH1 construct. The strategy involved annealing two complementary oligonucleotide primers, each containing the desired mutation, to opposite strands of the wild-type construct. The primers were then extended by the high fidelity *Pfu* DNA polymerase, resulting in a high specific mutation efficiency with a low level of random mutations. Finally, the parental DNA, which was *dam* methylated, was digested with *DpnI*, a restriction enzyme specific for methylated or hemi-methylated DNA, to select for mutation-containing plasmids.

Liposome-mediated transfection was chosen for DNA transfer into rat GH3 and human HeLa cells owing to its simplicity and efficiency. The reagent used for the transient transfection of the GH3 cells was TfxTM-50. This contained a mixture consisting of synthetic cationic lipid molecule (N,N,N',N'-tetramethyl-N,N'-bis(2-hydroxyethyl)-2,3-di(oleoyloxy)-1,4-butanediammonium iodide) and L-dioleoyl phosphatidylethanolamine (DOPE). On hydration with water, these lipids form multilamellar vesicles, which associate with nucleic acids and facilitate their transfer into cells. Cells were plated out using a 96 well plate format. Confluent cells were removed from culture flasks, diluted with fresh medium and calculated to a cell density of 160% confluence per well. A volume of 200µl of diluted cells was aliquoted into each well and the plate incubated at 37°C in the presence of boxes containing moistened paper overnight. This resulted in the cells being approximately 80% confluent when transfected the following day.

15

The transfection mixture contained serum-free medium, DNA (pGL3-GH1 and pRL-CMV) and TfxTM-50 Reagent. A total volume of 90µl per well was prepared containing 0.25µg of pGL3 construct, 2ng of pRL-CMV, and 0.5µl of TfxTM-50 Reagent (this provided the optimised 3:1 ratio of TfxTM-50 Reagent to DNA required). The medium and DNA were mixed first, followed by the TfxTM-50 Reagent. The solution was vortexed immediately and incubated for 20 minutes at room temperature. At the 15 minute stage, the cultured wells were taken from the incubator and the growth medium removed. The TfxTM-50 Reagent/DNA mixture was briefly vortexed before 90µl was added to each well. The plates were replaced in the incubator for 1 hour before 200µl of pre-warmed (37°C) complete medium was added to each well. The cells were replaced in the incubator for a further 24 hours before being lysed for the reporter assay. Transfection of HeLa cells was essentially the same as for the GH3 cells. The difference was that TfxTM-20 was used instead of TfxTM-50, 1ng of pRL-CMV was co-transfected and the cells were calculated to a cell density of 60% confluence per well.

30

Cultured, transfected cells were taken from the 37°C incubator and the growth medium removed before the addition of 50µl of phosphate buffered saline (PBS). The plate was gently swirled before the rinse solution was removed. A 20µl volume of passive lysis buffer was added to each culture well, ensuring the cell monolayer was completely covered. The plate was placed on a rotating table and left at room temperature for 30 mins before being stored at -70°C. The plate was thawed and spun at 6000 rpm for 20 seconds. A microplate luminometer was programmed to perform a 2 second pre-measurement delay followed by a 10 second measurement period for each reporter assay. A 50µl volume of luciferase assay reagent II (from the Dual Luciferase Reporter Assay System (from Promega, UK)) was directly injected into the first well and the firefly luciferase activity was measured and recorded. A 50µl volume of Stop & Glo™ reagent was then injected and the *Renilla* luciferase activity was recorded. This procedure was repeated for each cell lysate.

15 **Example 5C – Assay of signal transduction activity of GH variants**

A HK293 cell clone was selected as the target for the GH variants to be studied in our bioassay, since these cells exhibit elevated expression of the GH receptor. Prior to the assay, the cells were placed into 24-well plates (100,000 cells per well) for 24 hours, then co-transfected with a STAT 5-responsive luciferase reporter gene construct and a constitutively expressed β-Gal plasmid (CMV promoter) to allow correction for transfection efficiency. After an overnight transfection, the cells were washed and incubated with variant and wild-type GH diluted to a known standard range of concentrations for 6 hours. During this period, activation of the GH receptor would cause STAT 5 activation and luciferase expression. Thus, expression of luciferase in the assay provides a measure of the degree of GH receptor activation *ie* the biological activity of the GH applied to the cells. After the 6 hour incubation period, the cells were lysed and the luciferase measured in a plate reading luminometer using standard methods (assay according to the method of Ross RJM *et al* in *Molec Endocrin* 11 265-73 (1997); kit supplied by Promega UK Ltd).

Example 6 – *GHI* Gene Mutations and Polymorphisms

The selection characteristics according to the present invention have, to date, led to the characterisation and identification of some 3 different and novel variants
5 (“mutations”- Table 7B) in the *GHI* gene that, on the basis of different types of evidence presented below, may be involved in the aetiology of short stature. These novel lesions comprise 1 missense mutation, and 2 different mutations in the promoter/ region.

10 In Table 7B, nucleotide numbering is based on the *GHI* reference sequence shown in Figure 5, in which the five exons of the human *GHI* coding sequence are shown in upper case; the translation initiation (ATG) and termination codons (TAG) are underlined; the poly(adenylation) signal is shown in bold and is underlined; the 3’ UTR boundary is at position +1642; and +1 = transcriptional initiation site. All
15 numbering of mutational lesions, polymorphisms and oligonucleotide primers referred to in the text (with the exception of the Locus Control Region; see Figure 4) can be related to the *GHI* reference sequence.

Table 7B - Growth hormone deficiency: *GHI* gene mutations and polymorphisms

Patient ^a	Promoter haplotype ^b					Mutation ^{b,c,d}					Reference	Polymorphisms ^{b,c,d}	
	-168 (T/C)	-75 (A/G)	-57 (G/T)	-31 (ΔG)	-6 (G/A)	-1 (T/A/C)	+3 (G/C)	+16 (A/G)	+26 (A/C)	+59 (T/G)			
7 (9)	T	A	G	G	G	T	G	A	A	T	ND	ND	ND
7 (10)	T	A	G	.	A	A	G	A	A	T	ND	IVS4 C → T 1243 3' UTR G → A 1607	IVS4 C → T 1243 3' UTR G → A 1607
10 (1)	T	G	G	G	G	A	G	A	A	T	Lys41Arg (AAG → AGG:731)	Unpublished	IVS4 T → A 1169
10 (6)	T	A	T	G	A	A	G	A	A	T	ND	Unpublished	IVS4 T → A 1169
12 (2)	T	A	G	G	G	A	G	A	A	T	ND	Unpublished	IVS4 T → A 1169
12 (4)	T	A	G	G	G	A	G	A	A	T	G → A -48	Unpublished	IVS4 C → T 1101 IVS4 T → A 1169
18 (1)	T	A	G	G	A	A	G	A	A	G	ND	Unpublished	IVS1 C → T 188
18 (2)	T	A	G	G	A	A	G	A	A	T	ND	Unpublished	IVS1 A → G 124 IVS1 A → T 128
34 (3)	C	A	G	G	A	A	G	A	A	T	ND	Unpublished	IVS4 T → A 1169
34 (4)	T	A	G	G	G	A	G	A	A	T	ND	Unpublished	IVS4 T → A 1169
35 (6)	T	A	G	G	G	A	G	A	A	T	ND	Unpublished	IVS4 T → A 1169
35 (8)	T	G	G	G	G	A	G	A	A	T	ND	Unpublished	IVS4 T → A 1169
53 (1)	T	A	G	G	A	A	G	A	A	T	Ser71Phe (tcc → ttc: 821)	Unpublished	ND
57 (1)	T	A	G	.	G	A	G	A	A	T	-60 G → A	Unpublished	IVS4 T → A 1169
57 (2)	T	A	G	G	G	A	G	A	A	T	ND	Unpublished	IVS4 T → A 1169
62 (1)	T	A	G	G	G	A	G	A	A	T	ND	Unpublished	IVS4 T → A 1169
62 (2)	C	A	G	G	G	A	G	A	A	T	Gln91Leu (CAG → CTG: 973)	Unpublished	IVS4 T → A 1169

(Table 7B continues over).

Patient ^a	-168 (T/C)	-75 (A/G)	-57 (G/T)	-31 (ΔG)	-6 (G/A)	-1 (T/A/C)	+3 (G/C)	+16 (A/G)	+26 (A/C)	+59 (T/G)		
71.1	T	A	G	G	G	A	G	A	A	T	G → A -48	IVS4 C → T 1101 IVS4 T → A 1169
71.2	T	A	G	-	A	A	G	A	A	T	ND	ND
72A.1	T	A	T	G	A	A	G	A	A	T	ND	ND
72A.2	T	A	G	-	A	A	G	A	A	T	ND	ND
78.1	T	A	G	G	G	A	G	A	A	T	ND	IVS4 T → A 1169
78.2	T	A	G	G	G	T	G	A	A	T	ND	ND
79.1	T	A	G	G	G	T	G	A	A	T	ND	ND
79.2	T	G	G	G	G	A	G	A	A	G	Thr-24Ala (ACA → GCA: 69)	Miyata et al ^e (1997) IVS4 T → A 1169
80.1	T	G	G	G	G	A	G	A	A	T	ND	IVS4 T → A 1169
80.2	C	A	G	G	G	T	G	A	A	T	ND	IVS4 T → A 1169
82.1	T	A	G	G	G	A	G	A	A	T	ND	ND
82.2	T	A	G	G	G	T	G	A	A	T	ND	IVS4 T → A 1169
83.1	T	A	G	G	G	A	G	A	A	T	G → A -48	IVS4 C → T 1101 IVS4 T → A 1169
83.2	T	A	G	G	G	A	G	A	A	T	ND	ND

Key:

IVS: intervening sequence (intron)

ND: no mutation or polymorphism detected

UTR: untranslated region

^a Patient (clone number)

^b Nucleotide numbering based on GH1 reference sequence. At -31, alternative alleles are presence or absence of a G.

^c Amino acid residue number and substitution, (nucleotide substitution and number based upon GH1 reference sequence).

^d IVS number, nucleotide change, base number

^e Miyata I, Cogan J, Prince MA, Kamijo T, Ogawa M, Phillips JA Detection of growth hormone defects by dideoxy fingerprinting (ddF) Endocrinol J. 44 149-154 (1997).

* The first time this mutation has been identified *in vivo*; previously identified *in vitro* as a result of alanine scanning mutagenesis (Cunningham *et al* USP 5 849 535 (1998)).

The *GHI* reference sequence is derived from Chen *et al.* (1989) that was accessed through Genbank (Accession Number: J03071). Of 15 patients analysed, mutations have been found in 6 of them. All mutations detected were found in the heterozygous state.

5

(a) Missense mutations

Two single base-pair substitutions were noted within the coding region of the *GHI* gene that served to change the amino acid encoded. One of these (Gln91Leu) is novel. Evidence for the pathological involvement of this missense mutation came from four sources: (i) the study of a control population, (ii) the nature of the amino acid substitution and the degree of evolutionary conservation of the residue in question, (iii) molecular modelling and (iv) the *in vitro* assay of the signal transduction activity.

10

(i) Studies of *GHI* coding sequence variation in controls

A total of 80 healthy British controls of Caucasian origin were screened for variants within the coding region of the *GHI* gene. Five examples of silent substitutions found in single patients were noted [GAC→GAT at Asp26, TCG→TCC at Ser85, TCG→TCA at Ser85, ACG→ACA at Thr123 and AAC→AAT at Asn109]. In addition, two missense substitutions were noted [AAC→GAC, Asn47→Asp; GTC→ATC, Val110→Ile, 4/160 alleles]; only the Val110→Ile substitution had been found in our patient study (patient 66). The Gln91Leu mutation was not found in the control population, consistent with its pathological relevance.

20

(ii) Nature of the amino acid substitution and evolutionary conservation of the residue involved

25

The probability that a missense mutation will come to clinical attention depends upon a number of factors including the sequence structure of the gene in question, the magnitude of the amino acid substitution, the precise location and immediate environment of the substituted residue within the protein molecule, and its resulting effects on the structure and function of the protein (Wacey *et al* Hum Genet 94 594-608 (1994)). In order to assess whether missense mutation detected is likely to be significant pathologically, the biophysical properties of the changes are examined individually (Table 7C).

30

Evidence for the involvement of missense mutations in pathology can be derived from evolutionary conservation data, since those amino acid residues that are evolutionarily conserved are likely to possess a biological function. Conversely, those residues that are not conserved evolutionarily are less likely to be of functional significance. Pathological lesions tend therefore to occur in evolutionarily conserved residues whereas neutral polymorphisms or rare variants do not (Wacey *et al, ibid*). The GH residue found to be involved in missense mutation (Gln 91) was therefore examined in terms of its evolutionary conservation through comparison with the orthologous GH protein sequences of 19 other vertebrates (Table 7C). The residue affected by mutation was found to be conserved, supporting the view that this lesion is of pathological significance.

Table 7C: Missense mutation, biophysical properties and evolutionary conservation of residue involved

Amino acid substitution	Biophysical properties of change (conservative/non-conservative)	Evolutionary conservation of amino acid residue in vertebrate GH proteins
Gln→Leu 91	NC: polar→hydrophobic	Conserved in all vertebrates except sea bream and rock cod (charged Arg)

Orthologous GH proteins compared

(% identical, % conservatively changed vs human in brackets)

20 Mouse (66,77), rat (64, 75), rabbit (66, 77), whale, dog (67, 78), pig (67, 78), sheep (66, 76), cow (66, 76), turkey (55, 74), chicken (56, 73), duck (55, 72), turtle, frog (45, 68), shark, sea bream, rock cod, salmon, carp (38, 57), goldfish (37, 57).

(iii) Missense mutations with putative functional consequences as adduced by molecular modelling

25 Missense mutations were modelled by simple replacement of the appropriate amino acid residue in the X-ray crystallographic structure of human growth hormone. The wild-type and mutant “structures” were then compared with respect to electrostatic interactions, hydrogen bonding, hydrophobic interactions and surface exposure.

Gln91 lies within helix 2 at its C-terminal end. The introduction of Leu increases hydrophobicity and may affect protein folding.

(iv) Assay of signal transduction activity of GH variants

5 A luciferase reporter gene assay system (according to the method of Ross RJM *et al* in *Molec Endocrin* 11 265-73 (1997)) was used to assay the signal transducing activity (biological activity) of the GH variants. For growth hormone to be biologically active, it must bind to two GH receptors and cause receptor dimerization. This then causes the activation of an intracellular tyrosine kinase known as JAK2. 10 JAK2, in turn, phosphorylates and thus activates the transcription factor STAT 5. Phosphorylated STAT 5 dimerizes, translocates to the nucleus and binds to STAT 5-responsive promoters thereby switching on the expression of GH-responsive genes. The assay of GH biological activity that we have used requires all stages of this pathway to be functional.

15

Table 7D: Assay of signal transduction activity of GH variants

Patient No.	Mutation	% WT	SEM	p vs WT
<i>Wild-type</i>	-	100	3	-
79	Thr-24Ala	92	5	NS
62	Glu91Leu	81	5	NS

Results are expressed as % activity as compared to wild-type at a dose of 1nM in the luciferase reporter gene assay (1nM = approx ED50 of wild-type GH in the assay).

20 p indicates the probability that the difference between what is observed and what occurs in the wild type is significant. NS indicates 'not significant'.

(b) Promoter mutations

25 Two novel promoter variants were detected in our patient cohort. One of the single base-pair substitutions (-60 G→A) and a -48 G→A substitution noted in 3 unrelated patients. Evidence for the authenticity of the lesions was sought by (i) studying the *GHI* promoter region in healthy controls, (ii) studying the degree of evolutionary conservation of the nucleotides affected in different mammalian species and (iii)

determining their effect on *GHI* promoter function *in vitro* by means of a luciferase reporter gene assay.

5 A recurring mutation (-48 G → A) was noted corresponding to 3/6 (50%) mutant alleles found in our patient sample. This is very encouraging in terms of the prospect for the rapid detection of frequent pathological lesions in the *GHI* gene.

(i) *GHI* promoter variants in controls

10 The *GHI* promoter region was screened for mutations in 157 healthy British controls of Caucasian origin. The only sequence change noted which corresponded to a mutation found in the patient sample was a G→A transition at -48 which was detected in 2 individuals. Three further substitutions specific to the control sample were found in single individuals (+62 A→G, -123 T→C and -373 G→A). Finally, a gene conversion event (minimum -57 to -31, maximum -168 to -6) was noted in a single individual which was also specific to the control
15 sample. Thus, many fewer changes were detected in the controls than in the patients, a finding consistent with the patient mutations being of pathological significance. The -60 G→A substitution was not found in controls, which argues for its pathological relevance.

(ii) Evolutionary conservation

20 DNA sequence, corresponding to 130 bp upstream of the transcriptional initiation site of the *GHI* gene, was available from 10 mammalian species. Where ascertainment was possible, nucleotide -60, which was mutated in patient 57, was found to be evolutionarily conserved. This finding is consistent with the functional importance of this nucleotide.

25

(iii) Luciferase reporter gene analysis of *GHI* promoter mutations

The -48 G→A mutation was assessed in terms of its ability to drive luciferase gene expression in a reporter gene assay (Table 7G). 6 replicates were performed in 3 different experiments (*ie* 18 replicates in total) in both rat pituitary GH3 cells and
30 human HeLa cells. The reporter gene expression assay was therefore not supportive of the pathological involvement of this lesion.

35

Table 7G: Putative Promoter Mutations v Reporter Gene Expression

Promoter <u>mutation</u>	Associated <u>haplotype</u>	Luciferase activity	
		Normalized to haplotype	Normalized haplotype \pm sem
		GH3	HeLa
G→A -60	19	ND	ND
G→A -48	2	90 \pm 16	107 \pm 18

CLAIMS

1. A detection method for detecting a variation in *GHI* effective to act as an indicator of GH dysfunction in an individual, which detection method comprises the steps of:
- 5 (a) obtaining a test sample comprising a nucleotide sequence of the human *GHI* gene from the individual; and
- (b) comparing the sequence obtained from the test sample with the standard sequence known to be that of the human *GHI* gene (Figure 6, SEQ ID NO:),
- 10 wherein a difference between the test sample sequence and the standard sequence indicates the presence of a variation (hereinafter “variant of *GHI*”) effective to act as an indicator of GH dysfunction
- characterised in that* the test sample is obtained from an individual who exhibits one or both of the following features: intra-uterine growth retardation (IUGR), defined as
- 15 insufficient foetal height velocity diagnosed by standard methods known in the art; and/or small for gestational age (SGA), defined as insufficient (small) foetal body size (weight and/or length) for gestational age diagnosed by standard methods known in the art.
- 20 2. A method according to claim 1, wherein the method for determining IUGR is an *in utero* assessment or an “at the time of birth” assessment.
3. A method according to claim 1 or claim 2, wherein IUGR determination comprises two direct intra-uterine growth assessments by taking two ultra-sound
- 25 measurements at different times during the gestation of the individual.
4. A method according to claim 1 or claim 2, wherein IUGR determination and/or SGA (length) comprises length of the individual assessed at birth and related to the standard length/height charts at gestation for any child.
- 30 5. A method according to claim 1, wherein the method for determining SGA comprises weight of the individual assessed at birth and related to the standard weight charts at gestation for any child.

6. A detection method according to any preceding claim, wherein the test sample is obtained from an individual having a birth weight and/or birth length below $-2SD$ for gestation at birth.
- 5 7. A detection method according to any preceding claim, wherein the test sample is obtained from an individual exhibiting one or more further criteria, in addition to IUGR and/or SGA, namely:
- 10 (i) growth failure, defined as a growth pattern [delineated by a series of height measurements; Brook CDG (Ed) Clinical Paediatric Endocrinology 3rd Ed, Chapter 9, p141 (1995, Blackwell Science)] which, when plotted on a standard height chart [Tanner *et al* Arch Dis Child 45 755-762 (1970)], predicts an adult height for the individual which is outside the individual's estimated target adult height range, the estimate being based upon the heights of the individual's parents; and/or
- 15 (ii) height velocity below the 25th centile for age; and/or
- (iii) bone age delay according to the Tanner-Whitehouse scale of at least two years, when compared with chronological age except in either children of five or fewer years old or those exhibiting clinical evidence of pubertal development; and/or
- 20 (iv) no other disorder known to cause IUGR or SGA, or inclusion in criteria (i) to (iii) above; and/or
- (v) a clinical phenotype that resulted in sufficient clinical concern to have warranted GH secretion testing.
8. A method according to claim 7, wherein each of (i), (ii), (iv) and (v) are satisfied with respect to the individual.
- 25 9. A method according to claim 7 or 8, wherein the bone age delay is in the range of from 2 to 4 years, when compared with chronological age.
10. A method according to any preceding claim, wherein the individual exhibits
- 30 normal results in a standard growth hormone function test.
11. A detection method according to any preceding claim, wherein the test sample comprises genomic DNA extracted, by standard procedures, from patient lymphocytes buccal smears, blood samples or hair.

12. A method according to any preceding claim, wherein the detection method comprises any sequencing method for determining the sequence of the *GHI* gene of an individual.

5

13. A method according to any preceding claim, wherein the detection method comprises:

(c) PCR amplification of the *GHI* gene of the individual using (i) a *GHI* gene-specific fragment, being a fragment unique to the *GHI* gene whose sequence is not found in the four other paralogous (non-*GHI*) genes in the GH cluster, and (ii) one or more *GHI* gene-specific primers which cannot bind to the homologous flanking regions in the four other paralogous (non-*GHI*) genes in the GH cluster.

14. A method according to any preceding claim, wherein the *GHI* gene-specific primers are selected from GH1F (5' GGGAGCCCCAGCAATGC 3'; -615 to -599) and GH1R (5' TGTAGGAAGTCTGGGGTGC 3'; +2598 to +2616).

15. A method according to any preceding claim, wherein the detection method comprises PCR amplification of the entire *GHI* gene of the individual and nested PCR of overlapping constituent fragments of the *GHI* gene of the individual.

16. A method according to any preceding claim, wherein the detection method comprises PCR amplification of all or a fragment of genomic DNA spanning the Locus Control Region of the *GHI* gene.

25

17. A method according to any preceding claim, wherein the detection method comprises mutational screening of all or a fragment of the individual's *GHI* gene by DHPLC.

18. A detection method according to any preceding claim, which detection method further comprises the use of one or more primer(s) selected from:

CTC CGC GTT CAG GTT GGC (GHD1F);

AGG TGA GCT GTC CAC AGG (GHD1R);

30

- CTT CCA GGG ACC AGG AGC (GHD2R);
 CAT GTA AGC CAA GTA TTT GGC C (GHD3F);
 GGA GAA GGC ATC CAC TCA CGG (GHD4R);
 TCA GAG TCT ATT CCG ACA CCC (GHD5F);
 5 CGT AGT TCT TGA GTA GTG CGT CAT CG (GHD6R);
 TTC AAG CAG ACC TAC AGC AAG TTC G (GHD7F);
 GTGCCCCAAGCCTTTCCC (LCR15: 1159-1177);
 TGTCAGATGTTTCAGTTCATGG (LCR13: 1391-1412);
 CCTCAAGCTGACCTCAGG (LCR25: 1346-1363);
 10 GATCTTGGCCTAGGCCTCG (LCR23: 1584-1602);
 LCR 5A (5' CCAAGTACCTCAGATGCAAGG 3');
 LCR 3.0 (5' CCTTAGATCTTGGCCTAGGCC 3');
 LCR 5.0 (5' CCTGTCACCTGAGGATGGG 3');
 LCR 3.1 (5' TGTGTTGCCTGGACCCTG 3');
 15 LCR 3.2 (5' CAGGAGGCCTCACAAGCC 3');
 LCR 3.3 (5' ATGCATCAGGGCAATCGC 3')
 GH1G5 (5' GGTACCATGGCTACAGGTAAGCGCC 3');
 GH1G3 (5' CTCGAGCTAGAAGCCACAGCTGCCC 3');
 BGH3 (5' TAGAAGGCACAGTCGAGG 3');
 20 GH1R5 (5' ATGGCTACAGGCTCCCGG 3'); and
 GH1R3 (5' CTAGAAGCCACAGCTGCCC 3').

19. A screening method for screening a patient suspected of having dysfunctional GH, which screening method comprises the steps of:
- 25 (a) obtaining a test sample comprising a nucleotide sequence of the human *GHI* gene or a polypeptide encoded thereby from the patient; and
- (b) comparing a region of the sequence obtained from the test sample with the corresponding region of a predetermined sequence
- characterised in that* the predetermined sequence is selected from a variant of *GHI* or
- 30 polypeptide encoded thereby detectable according to a method according to any of claims 1 to 18.

20. A screening method according to claim 19, wherein the predetermined sequence is an oligonucleotide having a nucleic acid sequence corresponding to a

region of a variant *GHI* gene, which region incorporates at least one variation when compared with the corresponding region of the wild type sequence.

21. A screening method according to claim 19 or 20, comprising:

- 5 (a) obtaining a first test sample from an individual; and
(b) comparing the *GHI* gene or a polypeptide encoded thereby, or fragment therefrom, in the first test sample to the corresponding gene or a polypeptide encoded thereby, or fragment therefrom of a *GHI* variant obtainable from a second test sample derived from an individual who exhibits one or both of the following features: intra-
10 uterine growth retardation (IUGR), defined as insufficient foetal height velocity diagnosed by standard methods known in the art; and/or small for gestational age (SGA), defined as insufficient (small) foetal body size (weight and/or length) for gestational age diagnosed by standard methods known in the art.

15 22. A screening method according to any of claims 19 to 21, wherein the test sample comprises genomic DNA.

23. A screening method according to any of claims 20 to 22, wherein the comparison step includes the step of sequencing the appropriate region of the *GHI* gene and/or employs DNA chip technology wherein the chip is a miniature parallel
20 analytical device that is used to screen simultaneously either for multiple known mutations or for all possible mutations, by hybridisation of labelled sample DNA.

24. A screening method according to any of claims 20 to 22, wherein the
25 comparison step comprises identification of the polypeptide by protein sequencing methods, including mass spectroscopy, micro-array analysis and pyrosequencing and/or antibody-based methods of detection, including ELISA.

25. A screening method according to any of claims 18 to 24, which employs one or
30 more 'surrogate marker(s)' that are indicative of or correlated to the presence of the variant marker of *GHI* or the *GH* variant.

26. A screening method or kit according to claim 25, wherein the 'surrogate marker' is or includes:

- (a) any biomolecule (including, but not limited to, nucleotides, proteins, including antibodies specific for the GH variant or the variant of GHI, sugars and lipids);
- (b) a chemical compound (including, but not limited to, drugs and metabolites thereof); and/or
- 5 (c) a physical characteristic,
whose absence, presence, or quantity in an individual is measurable and correlated with the presence of the GH variant or the variant of GHI.

10

15

20

25

30




Fig. 1




Fig. 2

-136





Fig. 3

Figure 4

cccatgccatggttggaaggcagagggctctgggtggtccctctttagatcttggccttaggcctcggacctgataa gggtacggtaccaacctccgtctccagaccaccaggagaaatctagaaccggatccggagcctggactatt	1-75
ggtggggccactctcaagggtgcaggccaggacctgagccacggaagtcaggggcagggggttaaggtttca ccacccccggtgagagtccccacgtccggtcctggactcgggtgccttcagtcctcccgctcctcccaattccaaagt	76-150
tccgaggaacagcccgttccgggagccccagatgtcttctgtttccagatgttccaaatgaaaaaacattt aggctcctgtcgggcaaggccccgtcgggtctacaagaagaacaaaggtctacaaggttacttttttgtaaa	151-225
ctctgaaaagctgtcagatgttcagttcatggaataaacagctcagaaaataaaacatcacctgaggtcagcttg gagactttcgacagctctacaagtcacagtaacctatttctgagctcttataattgtagtggaactccagtcgaac	226-300
agggccatggggccgcatgctggtgaggggtggctggagagagactgacccgggggagtggggcaaaatctggga tccgggtaccgggctacgaccactcccaccgacctctctgactggggccccctcacccccgttttagaccct	301-375
gtctcatggttaggaaataactctcctgagcccctaacggacagagtccttcaacttggggctagtgctc cagagtaccaaaatcctttatgagaaggactcgggattgctgtctcaggaagtaattgaaacccccgatcacagag	376-450
cccaaagtgggggtataactgggaaaggctggggcacacagtgtttgtgggggtgtgtgtgtgtgtatgt gggttcaaccccccatattgaccttccgaacccccgtgacacaaacccccccacacacacacacataca	451-525
gcatgctcacacaggtgtgtgctggaccctgtggtggggcctaacttgagctggtcctagggtcagcgg cgtacgagtggtccacacaacggacctgggacaccacacccccggatgagacctcgaccaggatccccgagtcgcc	526-600
actgtagggggcacggaggtggtggggggcagttggcaccctcctcaggtgacaggtgcgctaaaaatctcaga tgacatccccctgctcccaacacccccctcaaccctgggtaggaggtccactgtccacgcgatttagagtct	601-675

676-750
aatcaccactaaagaacttatccaggtaacccaaaaaaactacacctgtacccccagaaaaatattgaaataaaaaaattt
ttagtggtgatttcttgaataggtccattgggtttttttgtaggacatgggtctttataaactttattttttaaa

751-825
aaaaaaacaagtgagaaagcagctccactccagggaggaaagacacacacatcccgtggacaaggatgcagatgt
ttttttgttccactctcgtcgagggtgaggtccctccctctgtgtgtgtagggcacctgttcctacgtctaca

826-900
ggcctttgggcttcatcccatctatgccggcaggatctgtttcaggaggggcggaggcagcgggggccccca
cggaaaaccgaaagtaaggtaagtaaggccctccctagacaaaagtccctccccctcgtcggccccgggt

901-975
cggcctgcaggggttattgtcacattttgagccgtgctgttccctcactggtgacaacagccctgagccccattt
ggcggactcccaataaacactgtaaaactcggcacgacaaggagtgaccactgtgtcgggactcggggtaaa

976-1050
tgggctcatgatgccctttcttcccagaacaggaggcctcacaagcctacccctgcctctgccctcggctgccc
accgagtactacgggaaaagaagggtcttctccctcggagtgttcggatgggacggagacgggagccgacggg

1051-1125
ggggctcacatctgactctgacgacacctcccttccaggaaggcaacatcaaaaataaggaatgggggcccag
ccccgaagtgaagactgaagactgctgtggaggaaaggctcctccgtttagttttattccttaccctccggtc

1126-1200
ggtcgggcgaaaggacaagggtcagggggtgggaaagcaagaaaggcagccccccagccaccctaggatgcc
ccagccccgcttccctgttccccgagtcccccaaccttcgttcttccgtcgtgggggtcggatcctaagg

1201-1275
gggagggggaagaaacctcagggaaagagctcagaccctgcctccttctccagcccaggtgtcctggatctg
ccctcccccttcttgagtccttctctcgagtctgggacggaggaaggtcgggtccacagaccctagac

1276-1350
ctgggctgctgtgactgggaaagacctgctaagaaggactgggtttgagtcctgacccagcagtgtagcagcc
gaccgcagcagactgaccttcttgagacttcttccctgacccccaaactcaggactgggtcgtcacatcgtcgg

1351-1425
aggaaaacctccccaggttaccagtggttcttactaagggtggtcttgcctcccaacggagggtctgcacatg
tcctttggaggggtccaatggtcacaagagatgatcccaaccgagcgggttgcctccctcgcagacgtgtac

6/9

catcagggcaatcggcctggtctcaatgaccgggtgggtgcctgggggggaggggcatggctggcaagcagag
gtagtcccgttagcgcgaccagagtactggccaccacgagaccgccctcccgttaaccgaccggttctcgtctc 1426-1500

ttccctgcccacatgccaaacagcaccatgaggcaacaccccattcttaacctctcagtgaccaaggttcctcat
 aaggacggggtgtacggtgtcgtgggtactccgtgtggtaagaattggagagtcactggttccaaggagta 1501-1575

ttctgtaaaatagaaataagcccaatagcgcgtttttgtgtgttttctggggttttctgagacaagatct
 aaagcattttatctttatcgggttatcgcgcaaaaaaacaacaagaccaccaaaagactctgttctaga 1576-1650

tgctctgtgtccaggctggagtgagtggtgcaatctccattcaaggcaacctctgccacctggactcaagtga
 acgagacaacaggtccgacctcagtcaccacgttagaggttaagtcccgttgagacggtggacctgagttcact 1651-1725

ttcaaccacctcagcctcccagtagctgggactacaggtcatgctactacacctggctaactgtgtatttctt
 aagtgggtggagtcggagggtcatcgacctgatgtccagtagatgtggaccgattagacacataaagaa 1726-1800

gttagagacaggttttactatgttcccagggtggtcctcaaaactcctgagctcaagcagatccaccgccctcagcct
 catctctgccaaaatgatacaacgggtccgaccagagtttgaggactcgagttcgtaggtggcgagtcgga 1801-1875

cccaaagtgtggattacagggctgagccactgcgcccggcccaacagtgcggtggtcgaaggcagctgtgc
 gggttcacgaccctaattgccgactcggtagcgcggggccgggtgtcacgcaaccagttcccgtcgacacg 1876-1950

acattgaaggccatcctgcatctgaggtacttggatgtggtagggcagccctgagggagggaggtg
 tgtaacttccggtaggacgtagactccatgaaccacttacaccacctgcccgtgaggactcctcccgtcctcac 1951-2025

cgagg
 gctcc 2026-2030

PCR primers are marked in **bold** (42-1984 = 1942bp).
Sequencing primers are underlined (GHLCR3.1, 541-558; GHLCR3.2, 1006-1023;
 GHLCR3.3, 1422-1440; GHLCR5.0, 640-658)

Figure 5

-700	ctgtttcttg	gtttgtgtct	ctgctgcaag	tccaaggagc	tggggcaata	-651
-650	ccttgagtct	gggttcttcg	tccccagga	cctgggggag	cccagcaat	-601
-600	gctcaggaa	aggggagagc	aaagtgtggg	gttggttctc	tctagtggtc	-551
-550	agtgttgaa	ctgcatccag	ctgactcagg	ctgaccagc	agtcctcagc	-501
-500	agaagtggaa	ttcaggactg	aatcgtgctc	acaacccccca	caatctattg	-451
-450	gctgtgcttg	gccccttttc	ccaacacaca	cattctgtct	ggtgggtgga	-401
-400	ggttaaacad	gcggggagga	ggaaagggat	aggatagaga	atgggatgtg	-351
-350	gtcggtaggg	ggtctcaagg	actggctatc	ctgacatcct	tctccgcggt	-301
-300	caggttgcc	accatggcct	gcggccagag	ggcaccacg	tgacccttaa	-251
-250	agagaggaca	agttgggtgg	tatctctggc	tgacactctg	tgacacaacc	-201
-200	tcacaacact	ggtgacggtg	ggaagggaaa	gatgacaagc	cagggggcat	-151
-150	gatcccagca	tgtgtgggag	gagcttctaa	attatccatt	agcacaagcc	-101
-100	cgtcagtggc	cccatgcata	aatgtacaca	gaaacaggtg	ggggcaacag	-51
-50	tgggagagaa	ggggccaggg	tataaaaagg	gccacaaga	gaccagctca	-1
+1	aggatcccaa	ggcccaactc	cccgaaccac	tcagggtcct	gtggacagct	+50
+51	cacctagcgg	caATGGCTAC	AGgtaagcgc	ccctaaaatc	cctttgggca	+100
+101	caatgtgtcc	tgaggggaga	ggcagcgacc	tgtagatggg	acgggggac	+150
+151	taaccctcag	gtttggggct	tctgaatgtg	agtatcgcca	tgtaagcca	+200
+201	gtatttgcc	aatctcagaa	agctcctggt	ccctggaggg	atggagagag	+250
+251	aaaaacaac	agctcctgga	gcagggagag	tgctggcctc	ttgctctccg	+300
+301	gctccctctg	ttgccctctg	gtttctcccc	agGCTCCCGG	ACGTCCCTGC	+350
+351	TCCTGGCTTT	TGGCCTGCTC	TGCCTGCCCT	GGCTTCAAGA	GGGCAGTGCC	+400
+401	TTCCCAACCA	TTCCCTTATC	CAGGCTTTTT	GACAACGCTA	TGCTCCGCGC	+450
+451	CCATCGTCTG	CACCAGCTGG	CCTTTGACAC	CTACCAGGAG	TTTgtaagct	+500
+501	cttggggaat	gggtgcgcat	caggggtggc	aggaaggggt	gactttcccc	+550
+551	cgctgggaaa	taagaggagg	agactaagga	gctcaggggt	tttcccgaag	+600
+601	cgaaaatgca	ggcagatgag	cacacgctga	gtgaggttcc	cagaaaagta	+650
+651	acaatgggag	ctggtctcca	gcgtagacct	tggtgggagg	tccttctcct	+700
+701	agGAAGAAGC	CTATATCCCA	AAGGAACAGA	AGTATTCATT	CCTGCAGAAC	+750
+751	CCCCAGACCT	CCCTCTGTTT	CTCAGAGTCT	ATTCCGACAC	CCTCCAACAG	+800
+801	GGAGGAAACA	CAACAGAAAT	CCgtgagtgg	atgccttctc	cccaggcggg	+850
+851	gatgggggag	acctgtagtc	agagcccccg	ggcagcacag	ccaatgcccg	+900
+901	tccttcccct	gcagAACCTA	GAGCTGCTCC	GCATCTCCCT	GCTGCTCATC	+950
+951	CAGTCGTGGC	TGGAGCCCGT	GCAGTTCCTC	AGGAGTGTCT	TCGCCAACAG	+1000
+1001	CCTGGTGTAC	GGCGCCTCTG	ACAGCAACGT	CTATGACCTC	CTAAAGGACC	+1050
+1051	TAGAGGAAGG	CATCCAAACG	CTGATGGGGg	tgaggggtggc	gccaggggtc	+1100
+1101	ccaatcctg	gagccccact	gactttgaga	gctgtgtag	agaacactg	+1150
+1151	ctgccctctt	tttagcagtc	aggccctgac	ccaagagaac	tcaccttatt	+1200
+1201	cttcatttcc	cctcgtgaat	cctccaggcc	tttctctaca	ccctgaaggg	+1250
+1251	gagggaggaa	aatgaatgaa	tgagaaaggg	agggaaacagt	accaagcgc	+1300
+1301	ttggcctctc	cttctcttcc	ttcactttgc	agAGGCTGGA	AGATGGCAGC	+1350
+1351	CCCCGACTG	GGCAGATCTT	CAAGCAGACC	TACAGCAAGT	TCGACACAAA	+1400
+1401	CTCACACAAC	GATGACGCAC	TACTCAAGAA	CTACGGGCTG	CTCTACTGCT	+1450
+1451	TCAGGAAGGA	CATGGACAAG	GTCGAGACAT	TCCTGCGCAT	CGTGCAGTGC	+1500
+1501	CGCTCTGTGG	AGGGCAGCTG	TGGCTTCTAG	ctgcccgggt	ggcatccctg	+1550
+1551	tgaccctcc	ccagtgcctc	tcctggccct	ggaagtggc	actccagtgc	+1600
+1601	ccaccagcct	tgtectaata	aaattaagtt	gcatcatttt	gtctgactag	+1650
+1651	gtgtccttct	ataatattat	gggggtggagg	gggggtggtat	ggagcaaggg	+1700

```
+1701 gcaagttggg aagacaacct gtagggcctg cgggggtctat tcgggaacca +1750
+1751 agctggagtg cagtggcaca atcttggctc actgcaatct ccgcctcctg +1800
+1801 ggttcaagcg attctcctgc ctcagcctcc cgagttggtg ggattccagg +1850
+1851 catgcatgac caggctcagc taatTTTTgt tTTTTggta gagacggggg +1900
+1901 ttcaccatat tggccaggct ggtctccaac tcctaattctc aggtgatcta +1950
+1951 cccaccttgg cctcccaaat tgctgggatt acaggcgtga accactgctc +2000
+2001 ccttccctgt ccttctgatt ttaaataaac tataaccagca ggaggacgctc +2050
+2051 cagacacagc ataggctacc tgccatgcc aaccgggtggg acatttgagt +2100
+2101 tgcttgcttg gcaactgctc ctcatgcggt gggteccactc agtagatgcc +2150
+2151 tgttgaattc ctgggcctag ggctgtgcc gctgcctcgt cccgtcacct +2200
+2201 tctggcttct tctctccctc catatcttag ctgttttctc catgagaatg +2250
+2251 ttccaaattc gaaatttcta ttaaccatt atatatttac ttgtttgcta +2300
+2301 ttatctctgc ccccagtaga ttgtagctc cagaagagaa aggatcatgt +2350
+2351 cttttgctta tctagatatg cccatctgcc tggtaacaatc tctggcacat +2400
+2401 gttacaggca acaactactt gtggaattgg tgaatgcatg aatagaagaa +2450
+2451 tgagtgaatg aatgaataga caaaaggcag aaatccagcc tcaaagaact +2500
+2501 tacagtctgg taagaggaat aaaatgtctg caaatagcca caggacaggt +2550
+2551 caaaggaagg aggggctatt tccagctgag ggcaccccat caggaaagca +2600
+2601 ccccagactt cctacaacta ctagacacat ctcgatgctt ttcacttctc +2650
+2651 tatcaatgga tcgtctccct ggagaataat ccccaaagtg aaattactta +2700
+2701 gcacgtccag ttaggtagat ccttgtgtac ttcttggttg ttcagagatc +2750
+2751 atcaaccagt gcaaacaatc cccccatcaa tacacagcag tgctgcccc +2800
+2801 tctccccccg aggtcttccg aggccttcc tccgtgctg aacccctgg +2850
+2851 acatatcata tggcaaactg aagtgtcaa cgagatatag gaagtgaaac +2900
+2901 acgatgtaca ctgaaactg caatacaaat atgcagcatg aagtgcctcg +2950
+2951 gttcactaac ccgagctacg ctgggtgctt cttttctacc actttcctta +3000
```

Figure 6

Growth hormone 1
 Gene symbol : *GHI*
 Location : 17q

	1 2	
-26	ATG GCT ACA G↓GC TCC CGG ACG TCC CTG CTC CTG GCT TTT GGC CTG	-12
	Met Ala Thr G ly Ser Arg Thr Ser Leu Leu Leu Ala Phe Gly Leu	
-11	CTC TGC CTG CCC TGG CTT CAA GAG GGC AGT GCC TTC CCA ACC ATT	4
	Leu Cys Leu Pro Trp Leu Gln Glu Gly Ser Ala Phe Pro Thr Ile	
5	CCC TTA TCC AGG CTT TTT GAC AAC GCT ATG CTC CGC GCC CAT CGT	19
	Pro Leu Ser Arg Leu Phe Asp Asn Ala Met Leu Arg Ala His Arg	
	2 3	
20	CTG CAC CAG CTG GCC TTT GAC ACC TAC CAG GAG TTT ↓ GAA GAA GCC	34
	Leu His Gln Leu Ala Phe Asp Thr Tyr Gln Glu Phe Glu Glu Ala	
35	TAT ATC CCA AAG GAA CAG AAG TAT TCA TTC CTG CAG AAC CCC CAG	49
	Tyr Ile Pro Lys Glu Gln Lys Tyr Ser Phe Leu Gln Asn Pro Gln	
50	ACC TCC CTC TGT TTC TCA GAG TCT ATT CCG ACA CCC TCC AAC AGG	64
	Thr Ser Leu Cys Phe Ser Glu Ser Ile Pro Thr Pro Ser Asn Arg	
	3 4	
65	GAG GAA ACA CAA CAG AAA TCC ↓ AAC CTA GAG CTG CTC CGC ATC TCC	79
	Glu Glu Thr Gln Gln Lys Ser Asn Leu Glu Leu Leu Arg Ile Ser	
80	CTG CTG CTC ATC CAG TCG TGG CTG GAG CCC GTG CAG TTC CTC AGG	94
	Leu Leu Leu Ile Gln Ser Trp Leu Glu Pro Val Gln Phe Leu Arg	
95	AGT GTC TTC GCC AAC AGC CTG GTG TAC GGC GCC TCT GAC AGC AAC	109
	Ser Val Phe Ala Asn Ser Leu Val Tyr Gly Ala Ser Asp Ser Asn	
110	GTC TAT GAC CTC CTA AAG GAC CTA GAG GAA GGC ATC CAA ACG CTG	124
	Val Tyr Asp Leu Leu Lys Asp Leu Glu Glu Gly Ile Gln Thr Leu	
	4 5	
125	ATG GGG ↓ AGG CTG GAA GAT GGC AGC CCC CGG ACT GGG CAG ATC TTC	139
	Met Gly Arg Leu Glu Asp Gly Ser Pro Arg Thr Gly Gln Ile Phe	
140	AAG CAG ACC TAC AGC AAG TTC GAC ACA AAC TCA CAC AAC GAT GAC	154
	Lys Gln Thr Tyr Ser Lys Phe Asp Thr Asn Ser His Asn Asp Asp	
155	GCA CTA CTC AAG AAC TAC GGG CTG CTC TAC TGC TTC AGG AAG GAC	169
	Ala Leu Leu Lys Asn Tyr Gly Leu Leu Tyr Cys Phe Arg Lys Asp	
170	ATG GAC AAG GTC GAG ACA TTC CTG CGC ATC GTG CAG TGC CGC TCT	184
	Met Asp Lys Val Glu Thr Phe Leu Arg Ile Val Gln Cys Arg Ser	
185	GTG GAG GGC AGC TGT GGC TTC TAG	
	Val Glu Gly Ser Cys Gly Phe *	

专利名称(译)	人生长激素基因的序列变体和检测方法		
公开(公告)号	EP1444360A2	公开(公告)日	2004-08-11
申请号	EP2002779672	申请日	2002-11-12
[标]申请(专利权)人(译)	威尔士大学医学院		
申请(专利权)人(译)	威尔士学院杂志JOURNAL大学		
当前申请(专利权)人(译)	大学学院卡迪夫顾问有限公司.		
[标]发明人	COOPER DAVID NEIL UNIV OF WALES PROCTER ANNE M UNIV OF WALES GREGORY JOHN UNIV OF WALES MILLAR DAVID S UNIV OF WALES		
发明人	COOPER, DAVID, NEIL UNIVERSITY OF WALES PROCTER, ANNE M. UNIVERSITY OF WALES GREGORY, JOHN UNIVERSITY OF WALES MILLAR, DAVID S. UNIVERSITY OF WALES		
IPC分类号	G01N33/53 C12N15/09 C12Q1/68 C12Q1/6883 G01N37/00		
CPC分类号	C12Q1/6883 C12Q2600/156 C12Q2600/158 C12Q2600/172		
优先权	2001027213 2001-11-12 GB		
外部链接	Espacenet		

摘要(译)

本发明涉及天然存在的生长激素突变;用于检测它们的方法及其在筛选患者生长激素不规则性或用于产生适于治疗这种不规则性的变体蛋白质中的用途。在一个方面,公开了一种检测GH1变异的检测方法,该检测方法有效地作为个体GH功能障碍的指标,该检测方法包括以下步骤:

(a) 获得包含人的核苷酸序列的测试样品来自个体的GH1基因; (b) 将从测试样品中获得的序列与已知为人GH1基因的序列进行比较,其中测试样品序列和标准序列之间的差异表明存在变异(下文称为GH1的变体) ') 有效地作为GH1功能障碍的指标,其特征在于测试样品是从个体获得的,其中一种或两种:表现出子宫内生长迟缓(IUGR),定义为通过已知的标准方法诊断的足够的胎儿高度速度。艺术;和/或小于胎龄(SGA),定义为通过本领域已知的标准方法诊断的生殖年龄的不足(小)胎儿体型(体重和/或长度)。